IL87246A - Process for the manufacture of phosphorus containing unsaturated 2-amino-alkanoic acid derivatives novel compounds and pharmaceutical compoistions containing them - Google Patents
Process for the manufacture of phosphorus containing unsaturated 2-amino-alkanoic acid derivatives novel compounds and pharmaceutical compoistions containing themInfo
- Publication number
- IL87246A IL87246A IL8724688A IL8724688A IL87246A IL 87246 A IL87246 A IL 87246A IL 8724688 A IL8724688 A IL 8724688A IL 8724688 A IL8724688 A IL 8724688A IL 87246 A IL87246 A IL 87246A
- Authority
- IL
- Israel
- Prior art keywords
- amino
- lower alkyl
- alkyl
- hydroxy
- substituted
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 151
- 238000000034 method Methods 0.000 title claims description 103
- 230000008569 process Effects 0.000 title claims description 97
- 239000002253 acid Substances 0.000 title claims description 33
- 238000004519 manufacturing process Methods 0.000 title claims description 29
- 229910052698 phosphorus Inorganic materials 0.000 title description 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 title description 3
- 239000011574 phosphorus Substances 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 239
- 239000000203 mixture Substances 0.000 claims abstract description 109
- -1 amino acid compounds Chemical class 0.000 claims abstract description 103
- 150000003839 salts Chemical class 0.000 claims abstract description 102
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 101
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 91
- 239000001257 hydrogen Substances 0.000 claims abstract description 76
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 75
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 55
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 49
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 49
- 150000002367 halogens Chemical class 0.000 claims abstract description 49
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 49
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 23
- 125000003277 amino group Chemical group 0.000 claims abstract description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 230000003287 optical effect Effects 0.000 claims abstract description 11
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 9
- 125000003118 aryl group Chemical group 0.000 claims abstract description 9
- OKDOWCKDTWNRCB-PTYLAXBQSA-N [(e,4r)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)[C@H](N)\C=C(/C)CP(O)(O)=O OKDOWCKDTWNRCB-PTYLAXBQSA-N 0.000 claims abstract 3
- 229910000077 silane Inorganic materials 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 160
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 109
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 80
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 72
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 68
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 44
- 125000003282 alkyl amino group Chemical group 0.000 claims description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 37
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 26
- OKDOWCKDTWNRCB-GQCTYLIASA-N [(e)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)C(N)\C=C(/C)CP(O)(O)=O OKDOWCKDTWNRCB-GQCTYLIASA-N 0.000 claims description 20
- 239000007858 starting material Substances 0.000 claims description 20
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 18
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 14
- 125000001160 methoxycarbonyl group Chemical class [H]C([H])([H])OC(*)=O 0.000 claims description 14
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 claims description 13
- OKDOWCKDTWNRCB-SSDOTTSWSA-N [(4r)-4-amino-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)[C@H](N)C=C(C)CP(O)(O)=O OKDOWCKDTWNRCB-SSDOTTSWSA-N 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 10
- 125000005059 halophenyl group Chemical group 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- BDYHNCZIGYIOGJ-RXMQYKEDSA-N (2r)-2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(C)=C[C@@H](N)C(O)=O BDYHNCZIGYIOGJ-RXMQYKEDSA-N 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 8
- BDYHNCZIGYIOGJ-DUXPYHPUSA-N (e)-2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(/C)=C/C(N)C(O)=O BDYHNCZIGYIOGJ-DUXPYHPUSA-N 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 5
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 125000004494 ethyl ester group Chemical group 0.000 claims description 4
- 239000012433 hydrogen halide Substances 0.000 claims description 4
- 229910000039 hydrogen halide Inorganic materials 0.000 claims description 4
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 150000008282 halocarbons Chemical class 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- CXPMGWPAIXGDBU-XBXARRHUSA-N [(e)-4-amino-2-methyl-5-(2-methylpropoxy)-5-oxopent-2-enyl]phosphonic acid Chemical compound CC(C)COC(=O)C(N)\C=C(/C)CP(O)(O)=O CXPMGWPAIXGDBU-XBXARRHUSA-N 0.000 claims description 2
- CEXLPSTVRBWYFE-SOFGYWHQSA-N [(e)-4-amino-5-butoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCCCOC(=O)C(N)\C=C(/C)CP(O)(O)=O CEXLPSTVRBWYFE-SOFGYWHQSA-N 0.000 claims description 2
- JKKLPTLBOAXMTI-CSKARUKUSA-N [(e)-4-amino-5-hexoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCCCCCOC(=O)C(N)\C=C(/C)CP(O)(O)=O JKKLPTLBOAXMTI-CSKARUKUSA-N 0.000 claims description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 4
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims 2
- YKISDVQNWMCLRI-NSCUHMNNSA-N (e)-2-amino-2-methyl-5-phosphonopent-3-enoic acid Chemical compound OC(=O)C(N)(C)\C=C\CP(O)(O)=O YKISDVQNWMCLRI-NSCUHMNNSA-N 0.000 claims 1
- OSJIIRPRSWOLPK-DUXPYHPUSA-N N\C(\C(=O)O)=C\CCP(=O)(O)O Chemical compound N\C(\C(=O)O)=C\CCP(=O)(O)O OSJIIRPRSWOLPK-DUXPYHPUSA-N 0.000 claims 1
- UNDVIPRJDSAXGO-VQHVLOKHSA-N [(e)-4-amino-2-methyl-5-oxo-5-pentoxypent-2-enyl]phosphonic acid Chemical compound CCCCCOC(=O)C(N)\C=C(/C)CP(O)(O)=O UNDVIPRJDSAXGO-VQHVLOKHSA-N 0.000 claims 1
- OLUILSXZGHFHAI-HWKANZROSA-N [(e)-4-amino-5-methoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound COC(=O)C(N)\C=C(/C)CP(O)(O)=O OLUILSXZGHFHAI-HWKANZROSA-N 0.000 claims 1
- BDYHNCZIGYIOGJ-XWCPEMDWSA-N cgp-37849 Chemical compound OP(=O)(O)CC(/C)=C/[C@@H](N)C(O)=O BDYHNCZIGYIOGJ-XWCPEMDWSA-N 0.000 claims 1
- WNBNJKWDUCHCHR-FMIVXFBMSA-N methyl (3e)-4-(diethoxyphosphorylmethyl)-2-formamidohepta-3,6-dienoate Chemical compound CCOP(=O)(OCC)C\C(CC=C)=C\C(NC=O)C(=O)OC WNBNJKWDUCHCHR-FMIVXFBMSA-N 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 168
- 239000000243 solution Substances 0.000 description 123
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 96
- 238000001704 evaporation Methods 0.000 description 81
- 230000008020 evaporation Effects 0.000 description 81
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 71
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 43
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 37
- 229910052757 nitrogen Inorganic materials 0.000 description 33
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 32
- 239000000741 silica gel Substances 0.000 description 32
- 229910002027 silica gel Inorganic materials 0.000 description 32
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000012074 organic phase Substances 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 25
- 238000001816 cooling Methods 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 229910052938 sodium sulfate Inorganic materials 0.000 description 22
- 235000011152 sodium sulphate Nutrition 0.000 description 22
- 239000008346 aqueous phase Substances 0.000 description 17
- 239000000706 filtrate Substances 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 16
- 239000000543 intermediate Substances 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- XJYNFPFHNCSKPP-HWKANZROSA-N (e)-4-methyl-2-(methylamino)-5-phosphonopent-3-enoic acid Chemical compound CNC(C(O)=O)\C=C(/C)CP(O)(O)=O XJYNFPFHNCSKPP-HWKANZROSA-N 0.000 description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 125000005907 alkyl ester group Chemical group 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 10
- 238000001035 drying Methods 0.000 description 10
- 239000001117 sulphuric acid Substances 0.000 description 10
- 235000011149 sulphuric acid Nutrition 0.000 description 10
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- YYRXFAWZLZDPQY-DHZHZOJOSA-N ethyl (e)-5-[bis(2-chloroethoxy)phosphoryl]-2-formamido-4-methylpent-3-enoate Chemical compound CCOC(=O)C(NC=O)\C=C(/C)CP(=O)(OCCCl)OCCCl YYRXFAWZLZDPQY-DHZHZOJOSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- SJHCUXCOGGKFAI-UHFFFAOYSA-N tripropan-2-yl phosphite Chemical compound CC(C)OP(OC(C)C)OC(C)C SJHCUXCOGGKFAI-UHFFFAOYSA-N 0.000 description 8
- PXEMFROPBWDOOK-ZCFIWIBFSA-N (2r)-2-amino-7-phosphonohept-3-enoic acid Chemical compound OC(=O)[C@H](N)C=CCCCP(O)(O)=O PXEMFROPBWDOOK-ZCFIWIBFSA-N 0.000 description 7
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- YXMZCXDFKCARGB-MRXNPFEDSA-N ethyl (2r)-5-di(propan-2-yloxy)phosphoryl-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]pent-3-enoate Chemical compound CC(C)(C)OC(=O)N[C@@H](C(=O)OCC)C=C(C)CP(=O)(OC(C)C)OC(C)C YXMZCXDFKCARGB-MRXNPFEDSA-N 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 229910052751 metal Inorganic materials 0.000 description 6
- 239000002184 metal Substances 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- PAORVUMOXXAMPL-VIFPVBQESA-N (2r)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-VIFPVBQESA-N 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229910052794 bromium Inorganic materials 0.000 description 5
- 229920001429 chelating resin Polymers 0.000 description 5
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- STNJBCKSHOAVAJ-UHFFFAOYSA-N Methacrolein Chemical compound CC(=C)C=O STNJBCKSHOAVAJ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- STLGNXYCVPFIKI-FMIVXFBMSA-N [(e)-4-(benzylamino)-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound OP(=O)(O)CC(/C)=C/C(C(=O)OCC)NCC1=CC=CC=C1 STLGNXYCVPFIKI-FMIVXFBMSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- WRBPADWPDKAGRV-UHFFFAOYSA-N ethyl 5-prop-2-enyl-4,5-dihydro-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)C1N=COC1CC=C WRBPADWPDKAGRV-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 150000003008 phosphonic acid esters Chemical class 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 4
- PNNHSJSUDHGPCC-OAHLLOKOSA-N (2r)-7-di(propan-2-yloxy)phosphoryl-2-[(2-methylpropan-2-yl)oxycarbonylamino]hept-3-enoic acid Chemical compound CC(C)OP(=O)(OC(C)C)CCCC=C[C@H](C(O)=O)NC(=O)OC(C)(C)C PNNHSJSUDHGPCC-OAHLLOKOSA-N 0.000 description 3
- RZGWHFMRNRMJRF-RXMQYKEDSA-N (4s)-4-formyl-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound CC1(C)OC[C@@H](C=O)N1C(O)=O RZGWHFMRNRMJRF-RXMQYKEDSA-N 0.000 description 3
- OHEZEKDRMVBPMA-GQCTYLIASA-N (e)-2-(dimethylamino)-4-methyl-5-phosphonopent-3-enoic acid Chemical compound CN(C)C(C(O)=O)\C=C(/C)CP(O)(O)=O OHEZEKDRMVBPMA-GQCTYLIASA-N 0.000 description 3
- YKHIIZXBBJACFR-OWOJBTEDSA-N (e)-2-amino-6-phosphonohex-4-enoic acid Chemical compound OC(=O)C(N)C\C=C\CP(O)(O)=O YKHIIZXBBJACFR-OWOJBTEDSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- 101150041968 CDC13 gene Proteins 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 102000018899 Glutamate Receptors Human genes 0.000 description 3
- 108010027915 Glutamate Receptors Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 229940117975 chromium trioxide Drugs 0.000 description 3
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- WSEDKMDNNXRKHH-MDWZMJQESA-N ethyl (e)-5-di(propan-2-yloxy)phosphoryl-2-formamido-4-methylpent-3-enoate Chemical compound CCOC(=O)C(NC=O)\C=C(/C)CP(=O)(OC(C)C)OC(C)C WSEDKMDNNXRKHH-MDWZMJQESA-N 0.000 description 3
- NFAOACDFQKKBAT-RMKNXTFCSA-N ethyl (e)-5-dimethoxyphosphoryl-2-formamido-4-methylpent-3-enoate Chemical compound CCOC(=O)C(NC=O)\C=C(/C)CP(=O)(OC)OC NFAOACDFQKKBAT-RMKNXTFCSA-N 0.000 description 3
- APINPQMNSPWPGH-UHFFFAOYSA-N ethyl 2-formamido-3-hydroxy-4-methylpent-4-enoate Chemical compound CCOC(=O)C(NC=O)C(O)C(C)=C APINPQMNSPWPGH-UHFFFAOYSA-N 0.000 description 3
- FPULFENIJDPZBX-UHFFFAOYSA-N ethyl 2-isocyanoacetate Chemical compound CCOC(=O)C[N+]#[C-] FPULFENIJDPZBX-UHFFFAOYSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- YKPZTHXPYPFOMI-SSDOTTSWSA-N (2r)-2-amino-4-methyl-7-phosphonohept-3-enoic acid Chemical compound OC(=O)[C@H](N)C=C(C)CCCP(O)(O)=O YKPZTHXPYPFOMI-SSDOTTSWSA-N 0.000 description 2
- TUMOUMLCWZEIRK-OWOJBTEDSA-N (e)-2-amino-5-phosphonopent-3-enoic acid Chemical compound OC(=O)C(N)\C=C\CP(O)(O)=O TUMOUMLCWZEIRK-OWOJBTEDSA-N 0.000 description 2
- DULQBMHSZXTSCK-QPJJXVBHSA-N (e)-4-methyl-5-phosphono-2-(propan-2-ylamino)pent-3-enoic acid Chemical compound CC(C)NC(C(O)=O)\C=C(/C)CP(O)(O)=O DULQBMHSZXTSCK-QPJJXVBHSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical class C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 2
- CFCNTIFLYGKEIO-UHFFFAOYSA-N 2-isocyanoacetic acid Chemical class OC(=O)C[N+]#[C-] CFCNTIFLYGKEIO-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 206010026749 Mania Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000008238 Muscle Spasticity Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical compound CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- RTIIUNJNKLHLBH-MLBSPLJJSA-N [(e)-5-ethoxy-2-methyl-5-oxo-4-(propan-2-ylamino)pent-2-enyl]phosphonic acid;hydrochloride Chemical compound Cl.CCOC(=O)C(NC(C)C)\C=C(/C)CP(O)(O)=O RTIIUNJNKLHLBH-MLBSPLJJSA-N 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N diisobutylaluminium hydride Substances CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- LUBJSNXMLKWACI-UKTHLTGXSA-N ethyl (e)-2-acetamido-5-di(propan-2-yloxy)phosphoryl-4-methylpent-3-enoate Chemical compound CCOC(=O)C(NC(C)=O)\C=C(/C)CP(=O)(OC(C)C)OC(C)C LUBJSNXMLKWACI-UKTHLTGXSA-N 0.000 description 2
- DFJZBKLKWPJYEQ-QPJJXVBHSA-N ethyl (e)-5-bromo-2-formamido-4-methylpent-3-enoate Chemical compound CCOC(=O)C(NC=O)\C=C(/C)CBr DFJZBKLKWPJYEQ-QPJJXVBHSA-N 0.000 description 2
- SXHDFHFNMJRHPE-UHFFFAOYSA-N ethyl 2-acetamido-3-hydroxy-4-methylpent-4-enoate Chemical compound CCOC(=O)C(NC(C)=O)C(O)C(C)=C SXHDFHFNMJRHPE-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- UZNGRHDUJIVHQT-UHFFFAOYSA-M magnesium;prop-1-ene;bromide Chemical compound [Mg+2].[Br-].C[C-]=C UZNGRHDUJIVHQT-UHFFFAOYSA-M 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 2
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- XRBCRPZXSCBRTK-UHFFFAOYSA-N phosphonous acid Chemical class OPO XRBCRPZXSCBRTK-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229910003446 platinum oxide Inorganic materials 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000001120 potassium sulphate Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 238000006884 silylation reaction Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 208000018198 spasticity Diseases 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- VOLGAXAGEUPBDM-UHFFFAOYSA-N $l^{1}-oxidanylethane Chemical compound CC[O] VOLGAXAGEUPBDM-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WMUZCMSSFFTVAO-MRXNPFEDSA-N (2r)-7-di(propan-2-yloxy)phosphoryl-4-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]hept-3-enoic acid Chemical compound CC(C)OP(=O)(OC(C)C)CCCC(C)=C[C@H](C(O)=O)NC(=O)OC(C)(C)C WMUZCMSSFFTVAO-MRXNPFEDSA-N 0.000 description 1
- KEJGAYKWRDILTF-JDDHQFAOSA-N (3ar,5s,6s,6ar)-5-[(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]-2,2-dimethyl-3a,5,6,6a-tetrahydrofuro[2,3-d][1,3]dioxol-6-ol Chemical compound O1C(C)(C)OC[C@@H]1[C@@H]1[C@H](O)[C@H]2OC(C)(C)O[C@H]2O1 KEJGAYKWRDILTF-JDDHQFAOSA-N 0.000 description 1
- MMSXASCDERFPKQ-SECBINFHSA-N (4R)-4-(4-carboxy-2-methylbut-1-enyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound C(=O)(O)CCC(=C[C@H]1N(C(OC1)(C)C)C(=O)O)C MMSXASCDERFPKQ-SECBINFHSA-N 0.000 description 1
- IKTAVBQLKZRIIE-SECBINFHSA-N (4R)-4-(5-bromopent-1-enyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound CC1(C)OC[C@@H](C=CCCCBr)N1C(O)=O IKTAVBQLKZRIIE-SECBINFHSA-N 0.000 description 1
- AHXMXVHUPMPSFD-OAHLLOKOSA-N (4R)-4-[5-di(propan-2-yloxy)phosphorylpent-1-enyl]-2,2-dimethyl-1,3-oxazolidine-3-carboxylic acid Chemical compound CC1(OC[C@H](N1C(=O)O)C=CCCCP(=O)(OC(C)C)OC(C)C)C AHXMXVHUPMPSFD-OAHLLOKOSA-N 0.000 description 1
- IKLNFASODYJDAD-JBGILVFVSA-N (E,2R)-2-amino-4-fluoro-5-phosphonopent-3-enoic acid Chemical compound OC(=O)[C@H](N)\C=C(\F)CP(O)(O)=O IKLNFASODYJDAD-JBGILVFVSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AEUHHZSVGBNBIL-JXMROGBWSA-N (e)-2-(benzylamino)-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(/C)=C/C(C(O)=O)NCC1=CC=CC=C1 AEUHHZSVGBNBIL-JXMROGBWSA-N 0.000 description 1
- JOVQDWASQDPUKS-DUXPYHPUSA-N (e)-2-amino-4-methyl-5-phosphanylpent-3-enoic acid Chemical compound PCC(/C)=C/C(N)C(O)=O JOVQDWASQDPUKS-DUXPYHPUSA-N 0.000 description 1
- WPVIMZXFCYKPCS-OWOJBTEDSA-N (e)-2-amino-5-phosphanylpent-3-enoic acid Chemical compound OC(=O)C(N)\C=C\CP WPVIMZXFCYKPCS-OWOJBTEDSA-N 0.000 description 1
- QHTABWCNPABQCM-HNQUOIGGSA-N (e)-2-amino-5-phosphonopent-4-enoic acid Chemical compound OC(=O)C(N)C\C=C\P(O)(O)=O QHTABWCNPABQCM-HNQUOIGGSA-N 0.000 description 1
- HFMTXRHUDKFQKW-OWOJBTEDSA-N (e)-2-amino-7-phosphonohept-4-enoic acid Chemical compound OC(=O)C(N)C\C=C\CCP(O)(O)=O HFMTXRHUDKFQKW-OWOJBTEDSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- BDYHNCZIGYIOGJ-FYTLMZHYSA-N (e,2s)-2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical compound OP(=O)(O)CC(/C)=C/[C@H](N)C(O)=O BDYHNCZIGYIOGJ-FYTLMZHYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- 125000001478 1-chloroethyl group Chemical group [H]C([H])([H])C([H])(Cl)* 0.000 description 1
- WLXGQMVCYPUOLM-UHFFFAOYSA-N 1-hydroxyethanesulfonic acid Chemical compound CC(O)S(O)(=O)=O WLXGQMVCYPUOLM-UHFFFAOYSA-N 0.000 description 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-N 138-42-1 Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- BDYHNCZIGYIOGJ-UHFFFAOYSA-N 2-amino-4-methyl-5-phosphonopent-3-enoic acid Chemical class OP(=O)(O)CC(C)=CC(N)C(O)=O BDYHNCZIGYIOGJ-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- NEAYIABCUAOVAD-UHFFFAOYSA-N 4,5-dihydro-1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1COC=N1 NEAYIABCUAOVAD-UHFFFAOYSA-N 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- 125000001999 4-Methoxybenzoyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C(*)=O 0.000 description 1
- PXACTUVBBMDKRW-UHFFFAOYSA-N 4-bromobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-N 0.000 description 1
- 125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 description 1
- AAXIFERZUUBPBF-UHFFFAOYSA-N 5-ethenyl-4,5-dihydro-1,3-oxazole-4-carboxylic acid Chemical class OC(=O)C1N=COC1C=C AAXIFERZUUBPBF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- LVQPCGJZIMATGL-UHFFFAOYSA-N C(C)OC(C(C=C(CP(=O)(O)O)/C)NC)=O Chemical compound C(C)OC(C(C=C(CP(=O)(O)O)/C)NC)=O LVQPCGJZIMATGL-UHFFFAOYSA-N 0.000 description 1
- RUWWJUSMZDVGBY-SNAWJCMRSA-N CCOC(=O)C(C)(/C=C/CP(=O)(O)O)N Chemical compound CCOC(=O)C(C)(/C=C/CP(=O)(O)O)N RUWWJUSMZDVGBY-SNAWJCMRSA-N 0.000 description 1
- VDESJQHWQJILIZ-MRVPVSSYSA-N COP(=O)(OC)CC(C)=C[C@H](CO)NC(O)=O Chemical compound COP(=O)(OC)CC(C)=C[C@H](CO)NC(O)=O VDESJQHWQJILIZ-MRVPVSSYSA-N 0.000 description 1
- YDFOGPNPGKZYMX-SNVBAGLBSA-N CO[C@@](C(=O)Cl)(C1=C(C(=C(C=C1)F)F)F)C Chemical compound CO[C@@](C(=O)Cl)(C1=C(C(=C(C=C1)F)F)F)C YDFOGPNPGKZYMX-SNVBAGLBSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 description 1
- 239000005751 Copper oxide Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- ISRDAKPAULPKHF-CQSZACIVSA-N [(2R)-7-di(propan-2-yloxy)phosphoryl-1-hydroxy-4-methylhept-3-en-2-yl]carbamic acid Chemical compound CC(C)OP(=O)(OC(C)C)CCCC(C)=C[C@H](CO)NC(O)=O ISRDAKPAULPKHF-CQSZACIVSA-N 0.000 description 1
- DXJAAGIXBYIUMF-GFCCVEGCSA-N [(2r)-5-di(propan-2-yloxy)phosphoryl-1-hydroxy-4-methylpent-3-en-2-yl]carbamic acid Chemical compound CC(C)OP(=O)(OC(C)C)CC(C)=C[C@H](CO)NC(O)=O DXJAAGIXBYIUMF-GFCCVEGCSA-N 0.000 description 1
- NPGZMOWWYWLSSM-QPJJXVBHSA-N [(E)-4-amino-5-butoxy-5-oxopent-1-enyl]phosphonic acid Chemical compound CCCCOC(=O)C(N)C\C=C\P(O)(O)=O NPGZMOWWYWLSSM-QPJJXVBHSA-N 0.000 description 1
- SIOOKCFIUBHSES-SOFGYWHQSA-N [(e)-4-(dimethylamino)-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)C(N(C)C)\C=C(/C)CP(O)(O)=O SIOOKCFIUBHSES-SOFGYWHQSA-N 0.000 description 1
- QOJDRQRJBWJLCI-WVLIHFOGSA-N [(e)-4-(dimethylamino)-5-ethoxy-2-methyl-5-oxopent-2-enyl]phosphonic acid;hydrochloride Chemical compound Cl.CCOC(=O)C(N(C)C)\C=C(/C)CP(O)(O)=O QOJDRQRJBWJLCI-WVLIHFOGSA-N 0.000 description 1
- VEZQLKLHSXDMQQ-ORCRQEGFSA-N [(e)-4-amino-5-(2-hydroxyethoxy)-5-oxopent-1-enyl]phosphonic acid Chemical compound OP(=O)(O)/C=C/CC(N)C(=O)OCCO VEZQLKLHSXDMQQ-ORCRQEGFSA-N 0.000 description 1
- FATNTWAEVZPURZ-HWKANZROSA-N [(e)-4-amino-5-ethoxy-5-oxopent-1-enyl]phosphonic acid Chemical compound CCOC(=O)C(N)C\C=C\P(O)(O)=O FATNTWAEVZPURZ-HWKANZROSA-N 0.000 description 1
- YYSVIGSJGPZGGX-ONEGZZNKSA-N [(e)-4-amino-5-ethoxy-5-oxopent-2-enyl]phosphonic acid Chemical compound CCOC(=O)C(N)\C=C\CP(O)(O)=O YYSVIGSJGPZGGX-ONEGZZNKSA-N 0.000 description 1
- VWIJHXGRMFJLMY-DHZHZOJOSA-N [(e)-4-amino-5-octoxy-5-oxopent-1-enyl]phosphonic acid Chemical compound CCCCCCCCOC(=O)C(N)C\C=C\P(O)(O)=O VWIJHXGRMFJLMY-DHZHZOJOSA-N 0.000 description 1
- VJWYDONQIVCGRL-RMKNXTFCSA-N [(e)-5-ethoxy-2-methyl-5-oxo-4-(propan-2-ylamino)pent-2-enyl]phosphonic acid Chemical compound CCOC(=O)C(NC(C)C)\C=C(/C)CP(O)(O)=O VJWYDONQIVCGRL-RMKNXTFCSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001980 alanyl group Chemical group 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910001508 alkali metal halide Inorganic materials 0.000 description 1
- 150000008045 alkali metal halides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000005092 alkenyloxycarbonyl group Chemical group 0.000 description 1
- 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000005189 alkyl hydroxy group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000005263 alkylenediamine group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 125000005101 aryl methoxy carbonyl group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 125000001942 asparaginyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000003939 benzylamines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
- 230000031709 bromination Effects 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- UCKORWKZRPKRQE-UHFFFAOYSA-N bromo(triethyl)silane Chemical compound CC[Si](Br)(CC)CC UCKORWKZRPKRQE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000006630 butoxycarbonylamino group Chemical group 0.000 description 1
- 125000006309 butyl amino group Chemical group 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229950005499 carbon tetrachloride Drugs 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910000431 copper oxide Inorganic materials 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- XYZMOVWWVXBHDP-UHFFFAOYSA-N cyclohexyl isocyanide Chemical compound [C-]#[N+]C1CCCCC1 XYZMOVWWVXBHDP-UHFFFAOYSA-N 0.000 description 1
- 238000005933 dealkoxycarbonylation reaction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical class [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- UJKARUREWUIXHT-RQJHMYQMSA-N ethyl (2r,3s)-2-amino-3-hydroxy-4-methylpent-4-enoate Chemical compound CCOC(=O)[C@H](N)[C@@H](O)C(C)=C UJKARUREWUIXHT-RQJHMYQMSA-N 0.000 description 1
- DNLZUTLRRUXEQL-ZJUUUORDSA-N ethyl (2r,3s)-3-acetyloxy-2-formamido-4-methylpent-4-enoate Chemical compound CCOC(=O)[C@H](NC=O)[C@@H](OC(C)=O)C(C)=C DNLZUTLRRUXEQL-ZJUUUORDSA-N 0.000 description 1
- AGYHBLNKYGNETA-ONEGZZNKSA-N ethyl (e)-2-amino-5-phosphanylpent-3-enoate Chemical compound CCOC(=O)C(N)\C=C\CP AGYHBLNKYGNETA-ONEGZZNKSA-N 0.000 description 1
- KZENFXVDPUMQOE-UHFFFAOYSA-N ethyl 2-(triphenyl-$l^{5}-phosphanylidene)propanoate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=C(C)C(=O)OCC)C1=CC=CC=C1 KZENFXVDPUMQOE-UHFFFAOYSA-N 0.000 description 1
- PLJKXOXIAWXHMJ-UHFFFAOYSA-N ethyl 2-[formyl(methyl)amino]-3-hydroxy-4-methylpent-4-enoate Chemical compound CCOC(=O)C(C(O)C(C)=C)N(C)C=O PLJKXOXIAWXHMJ-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000006331 halo benzoyl group Chemical group 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 125000001998 leucyl group Chemical group 0.000 description 1
- 125000001288 lysyl group Chemical group 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910001507 metal halide Inorganic materials 0.000 description 1
- 150000005309 metal halides Chemical class 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000002073 methionyl group Chemical group 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UYYCVBASZNFFRX-UHFFFAOYSA-N n-propan-2-ylcyclohexanamine Chemical compound CC(C)NC1CCCCC1 UYYCVBASZNFFRX-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 125000001181 organosilyl group Chemical class [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical class O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 125000005499 phosphonyl group Chemical group 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 125000002072 seryl group Chemical group 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RUPAXCPQAAOIPB-UHFFFAOYSA-N tert-butyl formate Chemical group CC(C)(C)OC=O RUPAXCPQAAOIPB-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000001239 threonyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- LUVCTYHBTXSAMX-UHFFFAOYSA-N tris(2-chloroethyl) phosphite Chemical compound ClCCOP(OCCCl)OCCCl LUVCTYHBTXSAMX-UHFFFAOYSA-N 0.000 description 1
- 125000001982 tryptophyl group Chemical group 0.000 description 1
- 125000002233 tyrosyl group Chemical group 0.000 description 1
- 125000002114 valyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/48—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof
- C07F9/4808—Phosphonous acids [RP(OH)2] including [RHP(=O)(OH)]; Thiophosphonous acids including [RP(SH)2], [RHP(=S)(SH)]; Derivatives thereof the acid moiety containing a substituent or structure which is considered as characteristic
- C07F9/4825—Acyclic unsaturated acids or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/302—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Unsaturated amino acid compounds of the formula <IMAGE> in which R1 denotes hydrogen, alkyl or hydroxyl, R2 denotes hydrogen, alkyl, halo(lower alkyl), hydroxy(lower alkyl), (lower alkoxy)(lower alkyl), aryl(lower alkyl), lower alkenyl, halogen or aryl, R3 denotes hydrogen, alkyl or aryl, R4 denotes hydrogen or alkyl, R5 represents carboxyl which may be esterified or amidated, R6 represents an amino group which is unsubstituted or substituted by lower alkyl or aryl(lower alkyl), A is alpha , omega -alkylene having 1 to 3 carbon atoms which is unsubstituted or substituted by alkyl or represents a direct bond and B denotes methylene or a bond, with the proviso that A represents alpha , omega -alkylene having 1 to 3 carbon atoms which is unsubstituted or substituted by alkyl if B represents a direct bond, and salts thereof are prepared by releasing in a compound of the formula <IMAGE> in which Z1 denotes protected or unprotected hydroxyl, Z2 denotes a group R1 or protected hydroxyl, Z5 denotes a group R5 or protected carboxyl, Z6 represents a protected group R6 and R1, R2, R3, R4, R5, R6, A and B have the abovementioned meanings, the protected group Z6 and, if desired, Z1, Z2 and/or Z5 by treatment with a tri(lower alkyl)halo- silane and, if desired, converting the compound obtained into another compound of the formula I, resolving a mixture obtained of optical isomers into the components and separating off the desired isomer and/or converting a free compound obtained into a salt or a salt obtained into the free compound or into another salt. (2R)-E-Ethyl 2-amino-4-methyl-5-phosphono-3-pentenoate and salts thereof are also described.
[EP0302826A2]
Description
REF : 999/88 87246/3 A PROCESS FOR THE MANUFACTURE OF PHOSPHORUS CONTAINING UNSATURATED 2-AMINO-ALKANOIC ACID DERIVATIVES, NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM 87246/5 The invention relates to a process for the manufacture of unsaturated amino acid compounds of formula in which Ri is hydrogen, alkyl or hydroxy, R2 is hydrogen, alkyl, halo-alkyl, hydroxy-alkyl, lower alkoxyalkyl, phenyl- louer alkyl or phenyl-lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkenyl, halogen, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, Rj underlined is hydrogen, alkyl, phenyl or phenyl substituted by lower alkyl, hydroxy, 28/JUL/88 lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or .by nitro, R, is hydrogen or alkyl, Rs is carboxy, lower alkoxycarbonyl , phenyl-lower alkoxycarbonyl, phenyl-lower alkoxy- carbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower a lkoxyca rbonyl substituted by carboxv or by lower alkoxycarbonyl , pyrid- yl me thoxyc rbon 1 , lower alkanoy loxy-subst luted me thoxyca bony 1 , lower alkoxymethoxycarbonyl substituted by lower a!kanoyloxy or by lower alkoxy, bicyc 10 [ 2 . 2 . 1 ) hep. loxyca rbonv -subst i t u ted methoxy carbonyl or lower alkoxycarboyloxy-louer alkoxy carbonyl or carbamoyl, lower alkyl- carbamoyl, di-lower a 1 ky lea rbamoy 1 or N-(di-lower a 1 ky lamino ) - 1 o e r a] ky J ca r'liamoy 1. R is an amino group thai is unsubst i tuted or substituted by lo er alkyl or by pheny 1 - 1 owe r alky] or p ony 1 - 1 owe r alky] - u l>s t 11 u I c by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-l wei aJkyl. yϋ rc:-: - ] o e r .iJky], amino-lo er a J ky 1 or by n tro. A is unsubit i tutod 1 ■ΌΊΜ .X 87246/3 - 2 - alkyl-substituted α , ω-alkylene having from 1 to 3 carbon atoms (C-atoms) underlined or is a direct bond, and B is methylene or a bond, with the proviso that 28/JUL/88 A is unsubstituted or alkyl-substituted α,ω-alkylene having from 1 to 3 C-atoms when B is a direct bond, and to the salts thereof, also to ( 2R) -E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester as such.
The compounds of formula I contain at least one chiral centre and may be in the form of enantiomers or enantiomeric mixtures, such as racemates, and if they contain more than one chiral centre, they may also be in the form of diastereoisomers or diastereoisomeric mixtures. The carbon-carbon double bond of the compounds according to the invention is in the transconfiguration in relation to R2 and R3 , or in relation to A and B, that is to say the compounds of formula I are compounds of the E-series.
Compounds of formula I in which Ri is hydrogen are phosphonous acids, those in which Ri is alkyl are phosphinic acids, and those in which Ri is hydroxy are phosphonic acids. In the names of the compounds of formula I that are to be regarded as substituted carboxylic acids, the prefixes "phosphino" (Ri is hydrogen), "phosphonyl" (Ri is alkyl) and "phosphono" (Ri is hydroxy) are used.
Esterified carboxy is, for example, lower alkoxycarbonyl ; lower alkoxy- carbonyl substituted in a position higher than the a-position by amino, by mono- or di-louer alkylamino or by hydroxy; a-carboxy-substituted lower alkoxycarbonyl; a-lower a lkoxyc a bony 1-subs i t u t ed lower alkoxycarbonyl, unsubs t i t u t ed or substituted benzyloxycarbony 1 , pyridy lmethoxy- carbonyl; for example pivaloy loxyme hoxyca bonyl ; lower a lkoxyme thoxyca r - bonyl substituted by lower alkanoyloxy or by lower alkoxy; bornyloxyca r- bonylmethoxyca bony 1 ; 3-phthalidoxycarbony 1 , l-(methoxy- or ethoxy-car- bonyloxy)-e thoxyca rbon l .
Especially preferred esters are, for example, lower alkyl esters having up to four carbon atoms, such as, for example, butyl or ethyl esters, lower alkanoy loxymethy 1 esters, such as, for example, pi va loyloxyme thy 1 ester, lower alkyl esters that have from two to four carbon atoms in each lower alkyl group and are substituted in a position higher than the α-position by di-lower alkylamino, such as, for example, 2-diethylamino-ethyl ester, and also pyridylmethyl esters, such as 3-pyridylmethyl ester.
Preferred amides are compounds of formula I in which Rs is carbamoyl, ethylcarbamoyl, diethylcarbamoyl, N-(2-diethylaminoethyl) carbamoyl or ( 3-diethylaminopropyl) carbamoyl .
Within the scope of this invention, alkyl is a saturated aliphatic hydrocarbon radical having, for example, up to 12 carbon atoms, but especially having up to 8 carbon atoms, the latter range also being represented by the term lower alkyl. α,ω-Alkylene having from 1 to 3 carbon atoms is methylene, 1,2-ethylene or 1 , 3-propylene . α,ω-Alkylene substituted by alkyl is substituted at any position. Thus, methylene substituted by alkyl is, for example, 1.1-ethylene, 1,1-butylene or 1 , 1-octylene , 1,2-ethylene substituted by alkyl is, for example, 1 , 2-propylene , 1 ,2-butylene, 2,3-butylene, 1.2-pentylene or 1 ,2-nonylene, and 1 , 3-propylene substituted by alkyl is, for example, 1 , 3-butylene, 1 , 3-pentylene or 1 ,3-decylene.
Amino substituted by lower alkyl or by phenyl-lower alkyl is mono- or di-lower alkylamino or phenyl-lower alkylamino.
Phenyl or phenyl substituted as indicated is, for example, unsubstituted or correspondingly substituted lower alkylphenyl, for example methyl-phenyl, hydroxyphenyl, halophenyl, for example 4-halophenyl , such as 4-chlorophenyl, benzyloxyphenyl, lower alkoxyphenyl, for example methoxy-phenyl, hydroxymethylphenyl, aminomethylphenyl or nitrophenyl.
The general terms used hereinbefore and hereinafter, unless defined otherwise, have the following meanings: The term "lower" indicates that groups or compounds so defined contain up to and including 8, preferably up to and including 4, carbon atoms.
Lower alkyl is, for example, Ci-Ci»alkyl, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert. -butyl, but can also be Cs-Cealkyl, such as n-pentyl, n-hexyl, n-heptyl or n-octyl, and is preferably methyl.
Phenyl-lower alkyl, also in definitions such as phenyl-lower alkylamino, is, for example, phenyl-Ci-Ci,alkyl in which phenyl has the meanings given above, and is especially, for example, unsubstituted phenyl-C1-C1,alkyl , such as benzyl or 1- or 2-phenylethyl.
Lower alkenyl contains preferably up to 6 carbon atoms and is bonded by way of an sp3 -hybridised carbon atom and is, for example, 2-propenyl, 2-or 3-butenyl or 3-pentenyl but can also be vinyl.
Lower alkoxy is especially Ci-Ci,alkoxy , such as methoxy, ethoxy, n-prop-oxy, isopropoxy, n-butoxy, isobutoxy or tert .-butoxy .
Halogen preferably has an atomic number of up to 35 and is especially chlorine, or also fluorine or bromine, but can also be iodine.
Halo-lower alkyl Is, for example, halo-Ci-Ci,alkyl, such as fluoromethyl , trifluoromethyl or 1- or 2-chloroethyl.
Hydroxy-lower alkyl is, for example, mono- or di-hydroxy-Ci-Cyalkyl , carries the hydroxy group(s) especially in a position higher than the a-position and is, for example, hydroxymethyl or especially mono- or di-hydroxy-C2-C7-alkyl , such as 2-hydroxyethyl , 3-hydroxy- or 2,3-di-hydroxy-propyl, 4-hydroxy- or 2 , -dihydroxy-butyl , or 5-hydroxy-, 2,5-di-hydroxy- or 3,5-dihydroxy-pentyl.
Lower alkoxy-lower alkyl is, for example, mono- or di-Ci-Ci,alkoxy-Ci-C7-alkyl, carries the lower alkoxy group(s), for example, especially in a position higher than the α-position and is especially Ci-Ci,-alkoxy-C2-Ci»-alkyl, for example, 2-methoxy-, 2-ethoxy-, 2-propoxy- or 2-iso-propoxy-ethyl, 3-methoxy- or 3-ethoxy-propyl or 3, 3-dimethoxy-, 3,3-di-ethoxy-, 2 , 3-dimethoxy- or 2 , 3-diethoxy-propyl or 4,4-dimethoxybutyl, but may also be methoxy-, ethoxy-, dimethoxy-, propoxy- or isopropoxy-methyl.
Mono- or di-lower alkylamino is, for example, N-Ci-Ci«alkylamino or N,N-di-Ci-Ci»alkylamino, such as methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino or butylamino.
Salts of compounds according to the invention are especially pharmaceutically acceptable non-toxic salts of compounds of formula I. Such salts are formed, for example, from the carboxy group present in compounds of formula I, and are especially metal or ammonium salts, such as alkali metal and alkaline earth metal salts, for example sodium, potassium, magnesium or calcium salts, and also ammonium salts with ammonia or suitable organic amines, such as lower alkylamines, for example methylamine, diethylamine or triethylamine, hydroxy-lower alkylamines, for example 2-hydroxyethylamine , bis-(2-hydroxyethyl)-amine, tris-(hydroxymethyl)-methylamine or tris-( 2-hydroxyethyl)-amine, basic aliphatic esters of carboxylic acids, for example 4-aminobenzoic acid 2-diethylaminoethyl ester, lower alkyleneamines, for example 1-ethyl-piperidine, lower alkylenediamines, for example ethylenediamine, cyclo- alkylaraines , for example dicyclohexylamine , or benzylamines , for example Ν,Ν' -dibenzylethylenediamine , benzyltrlmethylannnonium hydroxide, dibenzylamine or N-benzyl-B-phenylethylamine. Compounds of formula I having a primary or secondary amino group may also form acid addition salts, for example with preferably pharmaceutically acceptable inorganic acids, such as hydrohalic acids, for example hydrochloric acid or hydro-bromic acid, sulphuric acid, nitric acid or phosphoric acid, or with suitable organic carboxylic or sulphonic acids, for example acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, fumaric acid, maleic acid, tartaric acid, oxalic acid, citric acid, pyruvic acid, benzoic acid, mandelic acid, malic acid, ascorbic acid, pamoa acid, nicotinic acid, methanesulphonic acid, ethanesulphonic acid, hydroxy-ethanesulphonic acid, benzenesulphonic acid, 4-toluenesulphonic acid or naphthalenesulphonic acid.
It is also possible to use pharmaceutically unsuitable salts for isolation or purification. Only the pharmaceutically acceptable non-toxic salts are used therapeutically, and these are therefore preferred.
The compounds prepared in accordance with the invention have valuable pharmacological properties. They are, for example, active and selective antagonists of N-methyl-D-aspartic acid (NMDA)-sensitive excitatory amino acid receptors in mammals. They are therefore suitable for the treatment of diseases that respond to a blocking of NMDA-sensitive receptors, such as, for example, cerebral ischaetnia, muscular spasms (spasticity), convulsions (epilepsy), conditions of anxiety or manic conditions.
These advantageous effects may be demonstrated in in vitro or in in vivo test arrangements. For these, preferably mammals are used, for example mice, rats or monkeys, or tissue or enzyme preparations from such mammals. The compounds may be administered enterally or parentally, preferably orally; or subcutaneously, intravenously or intraperitoneally, for example in gelatin capsules or in the form of aqueous suspensions or solutions. The dosage to be used in vivo may range from 0.1 to 600 g/kg, preferably from 1 to 300 mg/kg. In vitro, the compounds may be used in -4 the form of aqueous solutions, the concentrations ranging from 10 to —8 10 molar solutions.
The inhibiting action on the NMDA-sensitive excitatory amino acid receptors may be determined in vitro by measuring, in accordance with G. Fagg and A. Matus, Proc. Nat. Acad. Sci., USA, 81_ , 6876-80 ( 1 984 ) , to what extent the bonding of L-s H-glutamic acid to NMDA-sensitive receptors is inhibited. In vivo, the inhibiting action on NMDA-sensitive excitatory amino acid receptors may be demonstrated by the inhibition of NMDA-induced convulsions in mice.
The anti-convulsive properties of the compounds according to the invention may furthermore be shown by their effectiveness in preventing audiogenical ly induced attacks in DBA/ 2 mice (Chapman et al . , Arznei-mittel-Forsch. 34 , 1 261 , 1984 ) .
The anti-convulsive properties may furthermore be shown by the effectiveness of the compounds according to the invention as electric shock antagonists in mice or in rats.
An indication of the anxiolytic activity of the compounds of the present invention is given by their pronounced effectiveness in the conflict model according to Cook/- Davidson ( Psychopharmacologia L5, 159-168 (1968)).
The pronounced effectiveness of the compounds of formula I depends to a surprisingly high extent on the configuration at the double bond. For example, the racemate of D-2-amino-5-phosphono-3-cis-pentenoic acid known from Agric. Blot. Chem. 4JL, 573-579 (1979), B. K. Park et at . , proves, for example in its ability to bond to the NMDA-sensitive receptor, to be far inferior to the racemate of the 2-amino-5-phosphono-3-trans-pentenoic acid the lower homolog of the 2-amino-4-methyl-5-phosphono-3-pentenoic acids according to the invention (in the Examples these compounds are referred to as compounds of the "E-series"). Compounds of the formula I, wherein the carbon atom carrying the group Rg has R-conf iguration, have been found to be especially active.
The manufacture of compounds of formula I in which R2 is hydrogen, alkyl or aryl is preferred.
The invention relates especially to a process for the manufacture of compounds of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, phenyl-lower alkyl that is unsubstituted or substituted in the phenyl moiety as indicated, lower alkenyl, halogen, phenyl or phenyl substituted as indicated, R3 is hydrogen, lower alkyl, phenyl or phenyl substituted as indicated, R<» is hydrogen or lower alkyl, R5 is carboxy, lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycar-bonyl, lower alkanoyloxy-substituted methoxycarbonyl, lower alkoxy-methoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[2.2.1 jheptyloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkylcar-bamoyl, di-lower alkylcarbamoyl or N-(di-lower alkylamino)-lower alkyl-carbamoyl, 6 is amino, or mono- or di-lower alkylamino, A is unsubstituted or lower alkyl-substituted ο,ω-alkylene having from 1 to 3 carbon atoms or is a bond, and B is methylene or a bond, with the proviso that A is other than a bond when B is a bond, the substituents of phenyl being selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl and nitro, and wherein "lower" groups possess up to and including 8 carbon atoms, and also to pharmaceutically acceptable salts thereof.
Preferred is the use of the process for the manufacture of compounds of formula I in which Ri to Ri» , A and B are as defined hereinbefore and, on the one hand, R5 is lower alkoxycarbonyl , or lower alkoxycarbonyl substituted by amino, mono- or di-lower alkylamino, hydroxy or by lower alkanoyloxy and Re is amino or lower alkylamino or, on the other hand, Rs is carboxy and R6 is amino, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
Also preferred is the use of the process for the manufacture of compounds of formula I in which Ri , Ri, to R6 and A and B are as defined directly hereinbefore and in which Rj and R3 , independently of one another, each represents hydrogen, lower alkyl, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy- - 9 - lower alkyl, amino-lower alkyl or by nltro, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
The invention relates especially to a process for the manufacture of compounds of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, Rj is hydrogen, lower alkyl, phenyl, halophenyl or phenyl-lower alkyl, R3 and R4 are hydrogen or lower alkyl and, on the one hand, R5 is alkoxycarbonyl or hydroxy-lower alkoxy-carbonyl and R6 is amino or mono-lower alkylamino or, on the other hand, R5 is carboxy and R6 is amino, A in each case being unsubstituted or lower alkyl-substituted α,ω- lkylene having from 1 to 3 carbon atoms or being a bond and B in each case being methylene or a bond, with the proviso that A is other than a bond when B is a bond, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
The invention relates especially to a process for the manufacture of compounds of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl or halophenyl, R3 is hydrogen or halophenyl, Ri, is hydrogen and, on the one hand, R5 is lower alkoxycarbonyl or hydroxy-lower alkoxycarbonyl and R6 is amino or mono-lower alkylamino or, on the other hand, R5 is carboxy and R6 is amino, A in each case being α,ω-alkylene having from 1 to 3 carbon atoms or being a bond and B in each case being methylene or a bond, with the proviso that A is other than a bond when B is a bond, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
The invention relates especially to a process for the manufacture of compounds of formula I in which Ri is hydrogen, lower alkyl or hydroxy, R2 is hydrogen or lower alkyl, R3 and Ri» are hydrogen and R5 is on the one hand lower alkoxycarbonyl or on the other hand carboxy, and R6 is amino, A in each case being α,ω-alkylene having from 1 to 3 carbon atoms - 10 - and B in each case being a bond, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
The invention relates most especially to a process for the manufacture of compounds of formula I in which Ri is hydroxy, R2 is hydrogen or lower alkyl, R3 and Ri» are hydrogen and R5 is lower alkoxycarbonyl or carboxy, R6 is amino, A is methylene and B is a bond, especially the R-enantiomers thereof in respect of the atom carrying the amino group, and pharmaceutically acceptable salts thereof.
The invention relates to the manufacture of the compounds mentioned specifically in the Examples and to the pharmaceutically acceptable salts thereof.
The process of the invention is characterised in that in a compound of formula in which Zi is free or protected hydroxy, Z2 is an Ri group or protected hydroxy, Z5 is an R5 group or protected carboxy, Ze is a protected R6 group, and Ri , R2, R3 , Ri*, R¾, Re, A and B are as defined hereinbefore, the protected groups Z and, where applicable, Zi , Z2 and/or Z5 are freed by treatment with a tri-lower alkylhalosilane and, if desired, the resulting compound is converted into a different compound of formula I, a resulting mixture of optical isomers is resolved into the components and the desired isomer is separated off, and/or a resulting free compound is converted into a salt or a resulting salt is converted into the free compound or into a different salt.
Protected hydroxy Z\ and/or Zz in intermediates of formula II is, for example, hydroxy etherified by an aliphatic alcohol, such as hydroxy etherified by a lower alkanol, lower alkenol or lower alkynol each of - 11 - which is unsubstituted or substituted by halogen or, in a position higher than the ot-position, by hydroxy, oxo, lower alkoxy, lower alkanoyloxy and/or by mono- or di-lower alkylamino, and is, for example, lower alkoxy, halo-lower alkoxy, or corresponding hydroxy-, oxo-, lower alkoxy-, lower alkanoyloxy- or mono- or di-lower alkylamino-lower alkoxy. Compounds of formula II in which Zi and/or Zz are etherified hydroxy are esters of the phosphorus-containing acid group and, depending on the meaning of Ri , are phosphonous acid esters, phosphinic acid esters or phosphonic acid esters. Preferred esters are the respective lower alkyl esters and hydroxy-lower alkyl esters.
Groups Ζε in intermediates of formula II are, for example, R6 groups substituted by acyl, that is to say acylamino that is unsubstituted or N-substituted by lower alkyl or by aryl-lower alkyl in which acyl is the acyl radical of an organic acid having, for example, up to 18 carbon atoms, especially an alkanecarboxylic acid that is unsubstituted or substituted, for example, by halogen, amino or by phenyl, or benzoic acid that is unsubstituted or substituted, for example, by halogen, lower alkoxy or by nitro, or of a carbonic acid semiester. Such acyl groups are, for example, lower alkanoyl, such as formyl, acetyl or propionyl, halo-lower alkanoyl, such as 2-haloacetyl , especially 2-fluoro-, 2-bromo-, 2-lodo-, 2,2,2-trifluoro- or 2,2,2-trichloro-acetyl, aroyl, such as unsubstituted or substituted benzoyl, for example benzoyl, halobenzoyl, such as 4-chlorobenzoyl, lower alkoxybenzoyl, such as 4-methoxybenzoyl, or nitrobenzoyl, such as 4-nitrobenzoyl. The following are also especially suitable: lower alkenyloxycarbonyl, for example allyloxycarbonyl, or especially lower alkoxycarbonyl that is unsubstituted or substituted in the 1- or 2-position, such as, especially, lower alkoxycarbonyl, for example tertiary butoxycarbonyl and also methoxy- or ethoxy-carbonyl, and also unsubstituted or substituted benzyloxycarbonyl, for example benzyloxycarbonyl or 4-nitrobenzyloxy-carbonyl, or aroylmethoxycarbonyl in which the aroyl group is benzoyl that is unsubstituted or substituted, for example, by halogen, such as bromine, for example phenacyloxycarbonyl or bromophenacyloxycarbonyl. - 12 - Furthermore, in a corresponding acylamino group Z , acyl may be alkanoyl-amino substituted by amino and/ or by phenyl, carbamoyl, carboxy, imidazolyl, lower alkylthio, tetrahydropyrrolyl, hydroxy, indolyl or by hydroxyphenyl , and thus includes, for example, the acyl radicals of amino acids, for example naturally occurring amino acids, such as alanyl, asparaginyl, aspartyl, glycyl, histidyl, isoleucyl, leucyl, lysyl, methionyl, phenylalanyl, prolyl, seryl, threonyl, tryptophyl, tyrosyl or valyl; also included are the acyl radicals of oligopeptides, for example di- or tri-peptides , such as oligopeptides of alanine, asparagine or aspartic acid.
Furthermore, protected amino Ζβ may be a diacylamino group. In this group diacyl is, for example, two acyl radicals of the definitions given hereinbefore, or diacyl is, for example, the acyl radical of an organic dicarboxylic acid having, for example, up to 12 carbon atoms, especially a corresponding aromatic dicarboxylic acid, such as phthalic acid. Such a group is especially phthalimido.
In addition, protected amino Z may also be amino substituted by substituted lower alkoxycarbonyl, such as amino substituted by 2-halo-lower alkoxycarbonyl, for example 2,2,2-trichloroethoxycarbonyl, 2-chloro-ethoxycarbonyl, 2-bromoethoxycarbonyl or 2-iodoethoxycarbonyl, or by 2-(tris-substituted silyl)-ethoxycarbonyl, such as 2-tri-lower alkyl-silylethoxycarbonyl, for example 2-trimethylsilylethoxycarbonyl or 2-(di-n-butyl-methyl-silyl)-ethoxycarbonyl, or by 2-triarylsilylethoxy-carbonyl, such as 2-triphenylsilylethoxycarbonyl, or etherified mercapto-amino or silylamino, or may be in the form of an enamino, nitro or azido group. An etherified mercaptoamino group is especially a phenylthioamino group that is unsubstituted or substituted by lower alkyl, such as methyl or tert. -butyl, lower alkoxy, such as methoxy, halogen, such as chlorine or bromine, and/or by nitro, or a pyridylthioamino group. Corresponding groups are, for example, 2- or 4-nitrophenylthioamino or 2-pyridylthio-amino. A silylamino group is especially an organic silylamino group. In such groups the silicon atom contains as substituent( s) preferably lower alkyl, for example methyl, ethyl, n-butyl or tert. -butyl, also aryl, for example phenyl. Suitable silyl groups are especially tri-lower alkyl- - 13 - silyl, especially trimethylsilyl or dimethyl-tert.-butylsilyl. Enamino groups contain at the double bond in the 2-position an electron-attracting substituent, for example a carbonyl group. Protecting groups of this kind are, for example, 1-acy1-lower alk-l-en-2-yl radicals in which acyl is, for example, the corresponding radical of a lower alkane-carboxylic acid, for example acetic acid, of a benzoic acid that is un-substituted or substituted, for example, by lower alkyl, such as methyl or tert. -butyl, lower alkoxy, such as methoxy, halogen, such as chlorine, and/or by nitro, or especially of a carbonic acid semiester, such as a carbonic acid lower alkyl semiester, for example methyl semiester or ethyl semiester, and lower alk-l-ene is especially 1-propene.
Corresponding protecting groups are especially 1-lower alkanoyl-prop-1-en-2-yl, for example l-acetyl-prop-l-en-2-yl , or 1-lower alkoxycarbonyl-prop-l-en-2-yl, for example l-ethoxycarbonyl-prop-l-en-2-yl.
Protected carboxy Z5 is customarily protected in esterified form, it being possible for the ester group to be cleaved under reductive, such as hydrogenolytic, or solvolytic, such as acidolytic or hydrolytic, such as acid-hydrolytic, basic-hydrolytic or neutral-hydrolytic, conditions. A protected carboxy group may furthermore be an esterified carboxy group that can be cleaved under physiological conditions or that can readily be converted into a different functionally modified carboxy group, such as into a different esterified carboxy group. Such esterified carboxy groups contain as esterifying groups especially silyl groups, especially tri-lower alkylsilyl groups, or lower alkyl groups that are suitably substituted in the 1- or 2-position. Preferred carboxy groups in esterified form are, inter alia, tri-lower alkylsilyloxycarbonyl, for example tri-methylsilyloxycarbonyl, (hetero-)arylmethoxycarbonyl having from 1 to 3 aryl radicals or having one monocyclic heteroaryl radical, these being unsubstituted or mono- or poly-substituted, for example, by lower alkyl, such as tert. -lower alkyl, for example tert. -butyl, halogen, for example chlorine, and/or by nitro. Examples of such groups are benzyloxycarbonyl that is unsubstituted or substituted, for example in the manner mentioned above, for example 4-nitrobenzyloxycarbonyl, diphenylmethoxycarbonyl or triphenylmethoxycarbonyl that is unsubstituted or substituted, for example in the manner mentioned above, for example diphenylmethoxycar- - 14 - bonyl, or picolyloxycarbonyl, for example 4-picolyloxycarbonyl , or fur-furyloxycarbonyl , such as 2-furfuryloxycarbonyl that is unsubstituted or substituted, for example in the manner mentioned above.
Protected hydroxy Zi and/or Zg is especially lower alkoxy, such as methoxy, ethoxy or isopropoxy, protected carboxy is especially tri-lower alkylsilyloxycarbonyl, such as trimethylsilyloxycarbonyl , and protected amino Z unsubstituted or substituted by lower alkyl or by aryl-lower alkyl is especially lower alkanoyla ino , especially formylamino, N-lower alkanoyl-N-lower alkylamino, especially N-formyl-N-lower alkylamino , for example N-formyl-N-methylamino, or lower alkoxycarbonylamino, preferably tertiary butoxycarbonylamino.
Tri-lower alkylhalosilanes are, for example, tri-lower alkyliodosilanes or, especially, tri-lower alkylbromosilanes, preferably those in which the lower alkyl groups are identical Ci-Ci,alkyl radicals. Trimethyl-bromosilane is preferred, with trimethyliodosilane as second choice.
Freeing the protected groups, that is to say freeing hydroxy from protected hydroxy groups Zi and/or Z2, freeing carboxy from protected carboxy groups Z5 and/or freeing amino that is unsubstituted or substituted by lower alkyl or by phenyl-lower alkyl from protected amino groups Ζβ by treatment with a tri-lower alkylhalosilane is effected, for example, in an inert solvent, such as a halogenated, preferably aliphatic hydrocarbon, for example dichloromethane or, less preferably, tri- or tetra-chloromethane, trichloroethane or tetrachloroethane , in a temperature range of approximately from -25u to +50°C, preferably from approximately 0°C to approximately 30°C, for example at temperatures in the region of room temperature, that is to say at from approximately 15°C to approximately 25°C, advantageously under substantially anhydrous conditions and under an inert gas, for example under argon or nitrogen.
Working up is carried out in a manner known per se, two purifying methods especially having proved advantageous. Either the crude product can be converted into a readily volatile derivative, for example by silylation, and recovered as such by distillation and then desilylated, or the crude - 15 - product can be treated with an agent that reacts with excess acid, such as hydrohalic acid, thereby removing it. Suitable agents are, for example, compounds to which a corresponding acid can be added, for example lower alkylene oxides (epoxides), such as propylene oxide.
If compounds of formula I in which R5 is esterified or amidated carboxy, such as lower alkoxycarbonyl or carbamoyl, are desired as end products, the starting materials of formula II and the process conditions can be so selected that although in the last step Zi, Z2 and Z¾ are freed, Z5, which represents the desired R5 group, remains unaffected.
An especially preferred process variant is accordingly directed to the manufacture of compounds of formula I in which R5 is Ci-C^alkoxycarbonyl and Re is amino. In this process variant the starting materials used are preferably compounds of formula II in which Zi and Z2 are lower alkoxy or lower alkoxy substituted in a position higher than the a-position by halogen, such as chlorine, Z5 is Ci-C^alkoxycarbonyl and Ze is lower alkanoylamino, such as formylamino, or lower alkoxycarbonylamino, such as tert.-butoxycarbonylamino. Starting from such compounds of formula II the freeing of the protected groups can be so controlled by treatment in an inert solvent, such as a halogenated hydrocarbon, for example dichloro- ethane, at temperatures in the region of room temperature, with a reagent such as trimethylbromosilane, and by subsequent treatment with a lower alkanol, such as ethanol, and a substance absorbing hydrogen halide, such as an aliphatic epoxide, especially an epoxy-lower alkane, for example propylene oxide, that compounds of formula I in which Ri is hydroxy, R5 is Ci-Ci*alkoxycarbonyl, R& is amino and the variables R2, R3 and Ri» are as defined for formula I, are obtained directly.
This process is especially preferred for the manufacture of compounds of formula I in which A is methylene or 1 , 3-propylene and B is a bond, R3 and Rij are hydrogen and R2 is alkyl having up to 4 carbon atoms, such as methyl. - 16 - Another especially preferred process variant is the manufacture of compounds of formula I in which R¾ is carboxy. In this case the starting materials used are preferably compounds of formula II in which Zi and Z2 are lower alkoxy or lower alkoxy substituted in a position higher than the a-position by halogen, such as chlorine, Z5 is optionally protected carboxy and Ze is lower alkoxycarbonylamino , especially a-branched lower alkoxycarbonylamino, such as tert.-butoxycarbonylamino. In this case, the carboxy group is preferably, but not necessarily, intermediately protected, for example by treatment with a silylation agent, such as an Ν,Ο-silyl-lower alkanoic acid amide, for example with N,0-trimethylsilyl-acetamide.
Intermediates of formula II are preferably manufactured by reacting a compound of formula in which R2, R3, Rt, , A and B are as defined for formula I, 5 has the meaning of R5 or is protected carboxy, Ζβ is a protected R6 group and X is reactive esterified hydroxy, with a compound of formula Z in which Zi is free or protected hydroxy, Z2 has the meaning of Ri or is protected hydroxy and R is an etherifying group, and can be used without being isolated or specially purified.
Compounds of formula III can be manufactured, for example, by reacting an N-protected aminomalonic acid ester of formula V Z$-?H-Z5 (V) , :6 - 17 - in which Z 5 and Zi are identical or different esterified carboxy groups, for example lower alkoxycarbonyl groups, in a manner known with a compound of formula in which X and X', independently of one another, each represents reactive esterified hydroxy, such as halogen. The resulting compounds of formula can be converted into compounds of formula III in which Ri» is hydrogen by hydrolysis, for example under hydrolytic conditions, such as the conditions of an acidic hydrolysis, for example with hydrohalic acids, such as hydrochloric acid, preferably with heating, and by decarboxylation, or by dealkoxycarbonylation, without previous hydrolysis, by heating in an aqueous aprotic solvent, such as dimethyl sulphoxide, in the presence of an alkali metal halide, such as sodium chloride.
This variant is accordingly especially suitable for producing compounds III in which Rt is hydrogen, Z5 is free or esterified carboxy and Ze is protected amino, such as lower alkanoylamino.
Intermediates III in which A is methylene that is unsubstituted or substituted by alkyl, B is a bond, X is halogen and Z& is formylamino can furthermore be produced by reacting a compound of formula wherein D denotes optionally alkylated methylidene, such as a corresponding α,Β-unsaturated aldehyde, for example acrolein or methacrolein, with an α-isocyanoacetic acid derivative, such as an α-isocyanoacetic acid lower alkyl ester. With suitable catalysis, such as with low valency - 18 - metal salts, that Is to say metal salts derived from metals of groups I and II of the Periodic Table of Elements, for example corresponding metal oxides or metal halides, such as zinc chloride, cadmium chloride, silver oxide or, preferably, copper oxide or complexes of gold-I-tetrafluoro-borate with aliphatic or cycloaliphatic isocyanides, for example bis-(cyclohexylisocyanide) gold-I-tetrafluoroborate, there are thus obtained in a manner known per se 5-vinyl-2-oxazoline-4-carboxylic acid derivatives, for example esters of formula which can be converted into the open-chained compounds of formula in which D is unsubstituted or alkyl-substituted methylidene. These compounds can in turn be converted by selective halogenation, such as bromination or chlorination, preferably with cooling and with displacement of the double bond in the manner of an allyl rearrangement, into compounds of formula III.
Another process for the manufacture of compounds II in which Ri» is hydrogen, A is methylene or 1 ,3-propylene and Rs is carboxy, is based on the principle that a compound of formula (XI) - 19 - In which R. and IL, are hydrogen or preferably lower alkyl, such as methyl, and R_ is an amino-protecting group, is condensed with a 2-R2-acetic acid ester or condensed first with a l-R2-ethene-metal compound, for example with isopropenylmagnesium bromide, and subsequently with an acetic acid ester, in the resulting compound of formula in which Z5 is esterified carboxy, for example lower alkoxycarbonyl, this group is reduced to hydroxyraethyl , for example by means of diiso-butylaluminium hydride, the hydroxyraethyl group is halogenated, for example brominated by means of tetrabro omethane/triphenylphosphine , the resulting compound of formula in which A denotes methylene or 1 , 3-propylene and X is halogen, for example bromine, is further reacted with a compound of formula IV, the oxazolidine ring is cleaved, for example, by means of an ion exchanger, such as Amberlyst 15®, and, in the resulting compound of formula in which 2$ is a protected amino group of formula RC-NH-(II'), the hydroxymethyl group is oxidised to carboxy in customary manner.
When carrying out the above-described processes for the manufacture of intermediates III and the further reaction of the same to form intermediates II it is not necessary to isolate all of the intermediate - 20 - stages. For example, especially the conversion of compounds X into com pounds III and the further reaction thereof with compounds IV to form intermediates II can advantageously be carried out in situ.
A preferred variant of the process of the invention accordingly consis of the following: a compound of formula in which R2, Rj, Ri», A and B are as defined for formula I, Z¾ has the meaning of R5 or is protected carboxy, Z is a protected R6 group, for example protected amino, and X is reactive esterlfied hydroxy, is reacted with a compound of formula in which Zi is free or protected hydroxy, Z2 has the meaning of Ri or is protected hydroxy and R is an etherifying group, the protected groups Ζβ and, where applicable, Zi , Z2 and/or Z5 are freed by treatment with a tri-lower alkylhalosilane, for example with trimethylbromosilane, and, if desired, a resulting compound of formula I is converted into a different compound of formula I and/or, if desired, a resulting compound of formula I is converted into a salt or a resulting salt is converted into a different salt or into a free compound of formula I and/or, if desired, an optical isomer is isolated from a mixture of stereoisomeric forms of a resulting compound of formula I or of a salt thereof.
A reactive esterlfied hydroxy group, such as X, is a hydroxy group esterlfied by a strong organic acid, for example a hydroxy group esterlfied by an aliphatic or aromatic sulphonic acid (such as a lower alkanesulphonic acid, especially methanesulphonic acid, trifluoromethane-sulphonic acid, especially benzenesulphonic acid, p-toluenesulphonic acid, p-bromobenzenesulphonic acid and p-nitrobenzenesulphonic acid) or - 21 - by a strong inorganic acid, such as, especially, sulphuric acid, or a hydrohalic acid, such as hydrochloric acid or, most preferably, hydriodic acid or hydrobromic acid.
Attention is drawn in this connection to the surprising finding that the manufacture of the intermediates II and their further reaction according to the invention to form the end products I can be carried out stereo-selectively. That is, neither in the reaction sequence III + IV -» II or Ila -> I, nor in the reaction sequences X -> III and XI -» XII → XIII → XIV -> II is there reversal of configuration or significant racemisation. The process of the invention is therefore excellently suitable for the direct manufacture of compounds of formula I with the preferred R-con-figuration at the carbon atom carrying the amino group R6 · The invention also relates to the manufacture of sterically homogeneous compounds of formula I and sterically homogeneous intermediates of formulae II, III, X, XI, XII, XIII and/or XIV.
According to another preferred process variant, a compound of formula is subjected to selective halogenation, for example by means of thionyl chloride, to form the corresponding intermediate III, and this is reacted in situ, that is to say without being isolated, with component IV.
As mentioned, compounds obtainable in accordance with the invention can be converted into different compounds of formula I. In particular, a free amino group R6 may be substituted, for example converted into an unsub-stituted or phenylated alkylamino group, free carboxy R5 may be esteri-fied, or esterified or amidated carboxy R5 may be converted into free carboxy, and/or free or esterified carboxy R5 may be converted into amidated carboxy. - 22 - To convert an amino group into an unsubstituted or phenylated alkylamlno group the amino group may be alkylated by substitution, for example with a reactive esterified optionally phenylated alkanol, such as an alkyl halide, or by reduction, such as with an aldehyde or ketone, and also with catalytically activated hydrogen or, in the case of formaldehyde, advantageously with formic acid as reducing agent.
Free carboxylic acids of formula I or salts thereof may be converted according to known processes by suitable alcohols or corresponding derivatives thereof into the corresponding esters, that is to say into compounds of formula I that are, for example, in the form of lower alkyl esters, aryl-lower alkyl esters, lower alkanoyloxymethyl esters or lower alkoxycarbonyl-lower alkyl esters.
For the esterification , a carboxylic acid may be reacted directly with a diazoalkane, especially diazomethane , or with a corresponding alcohol in the presence of a strongly acidic catalyst (for example a hydrohalic acid, sulphuric acid or an organic sulphonic acid) and/or of a dehydrating agent (for example dicyclohexylcarbodiimide) . Alternatively, the carboxylic acid may be converted into a reactive derivative, such as into a reactive ester, or into a mixed anhydride, for example with an acid halide (for example, especially an acid chloride), and this activated intermediate is reacted with the desired alcohol.
Compounds of formula I in which R5 is esterified carboxy, such as, especially, lower alkoxycarbonyl , for example ethoxycarbonyl , can be converted into compounds of formula I in which R5 is carboxy, for example by hydrolysis especially in the presence of inorganic acids, such as hydrohalic acids or sulphuric acid or, less preferably, aqueous alkalis, such as alkali metal hydroxides, for example lithium or sodium hydroxide. In this connection attention is drawn to the fact that also carboxy can be freed from esterified carboxy in such a manner that no significant racemisation occurs. This can be achieved especially by treatment with from approximately 0.2N to approximately 4N, for example approximately IN, that is to say from approximately 0.5N to approximately 2N, aqueous mineral acid, if necessary while heating, for example at from approxi- - 23 - mately 60°C to approximately boiling temperature, that is to say approximately 100°C. Surprisingly, the hydrolysis, for example, of phosphonic acid carboxylic acid lower alkyl esters of formula I, proceeds with a high yield even without the addition of acidic or basic reagents. A preferred process for the manufacture of carboxylic acids of formula I from the corresponding lower alkyl esters, such as the respective ethyl esters, therefore consists in acidic hydrolysis by treatment with from approximately 0.2N to approximately 4N aqueous mineral acid, for example hydrochloric acid, sulphuric acid, phosphoric acid or the like, and also in the - possibly autocatalytic - hydrolysis in water, preferably at elevated temperatures, such as with heating under reflux.
The above reactions are carried out according to standard methods in the absence or presence of diluents, preferably those that are inert towards the reagents and are solvents therefor, in the presence of catalysts, condensation agents or the other agents and/or in an inert atmosphere, at low temperature, room temperature or elevated temperature, preferably at the boiling point of the solvents used, at atmospheric or superatmos-pheric pressure.
The invention includes furthermore any variant of the present processes in which an intermediate obtainable at any stage of that process is used as starting material and the remaining steps are carried out, or the process is discontinued at any stage, or in which the starting materials are formed under the reaction conditions or in which the reactants are used in the form of their salts or optically pure antipodes. There should especially be used in these reactions those starting materials that result in the formation of the compounds mentioned hereinbefore as being especially valuable.
The invention relates also to novel starting materials and processes for their manufacture.
Depending on the choice of starting materials and methods, the novel compounds may be in the form of one of the possible optical isomers or in the form of mixtures thereof, for example depending on the number of - 24 - asymmetric carbon atoms they may be in the form of pure optical isomers, such as antipodes, or mixtures of optical isomers, such as racemates, or mixtures of diastereoisomers from which one antipode, if desired, may be isolated.
Resulting mixtures of diastereoisomers and mixtures of racemates may be separated in known manner on the basis of the physico-chemical differences between the constituents into the pure isomers, diastereoisomers or racemates, for example by chromatography and/or fractional crystallisation.
The resulting racemates (racemic diastereoisomers) may furthermore be separated into the optical antipodes according to methods known per se, for example by recrystallisation from an optically active solvent, with the aid of microorganisms or enzyme-catalyst in free or in an immobilised form or by reaction of an acidic end product with an optically active base that forms salts with the racemic acid, and separation of the salts obtained in this manner, for example on the basis of their different solubilities, into the diastereoisomers, from which the antipodes can be freed by the action of suitable agents. Basic racemic products can also be separated into the antipodes, for example by separation of the dia-stereoisomeric salts thereof, for example by fractional crystallisation of the d- or 1-tartrates thereof. Any racemic intermediate or starting material can be separated in a similar manner.
Finally, the compounds according to the invention are obtained either in free form or in the form of their salts. Any resulting base can be converted into a corresponding acid addition salt, preferably using a pharmaceutically acceptable acid or an anion-exchange preparation, or resulting salts can be converted into the corresponding free bases, for example using a stronger base, such as a metal or ammonium hydroxide or a basic salt, for example an alkali metal hydroxide or carbonate, or a cation-exchange preparation. A compound of formula I can also be converted into the corresponding metal or ammonium salts. These or other salts, for example the picrates, can also be used for the purification of resulting bases. The bases are converted into salts, the salts are - 25 - separated and the bases are freed from the salts. In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is mentioned in this Application, a corresponding salt of that compound is also included, provided that this is possible or appropriate under the given circumstances.
The compounds, including their salts, can also be obtained in the form of their hydrates or contain other solvents used for the crystallisation.
The pharmaceutical preparations according to the invention are those that are suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, for the treatment or prevention of diseases that respond to the blocking of NMDA-receptors, such as, for example, cerebral ischaemia, muscular spasms (spasticity), convulsions (epilepsy), conditions of anxiety or manic conditions. They comprise an effective amount of a pharmacologically active compound of formula I or a pharmaceutically acceptable salt thereof, on its own or in combination with one or more pharmaceutically acceptable carriers.
The pharmacologically active compounds of the invention can be used in the manufacture of pharmaceutical compositions that comprise an effective amount of the active compound on its own or in conjunction or admixture with excipients or carriers that are suitable for enteral or parenteral administration. Preferred are tablets and gelatin capsules that comprise the active constituent together with a) diluents, for example lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine, b) glidants, for example silicon dioxide, talc, stearic acid, the magnesium or calcium salt thereof and/or polyethylene glycol, for tablets also c) binders, for example magnesium aluminium silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, if desired d) dispersing agents or disintegrators, for example starches, agar, alginic acid or the sodium salt thereof, or foaming mixtures and/or e) absorbents, colouring agents, flavourings and sweeteners. Injectable preparations are preferably aqueous isotonic solutions or suspensions, and suppositories are advantageously produced from fatty emulsions or suspensions. These compositions may be sterilised - 26 - and/or contain adjuvants, such as preservatives, stabilisers, wetting agents or emulsifiers , solubilisers , salts for regulating the osmotic pressure and/or buffers. In addition they may also contain other therapeutically valuable substances. These preparations are manufactured according to conventional mixing, granulating or coating methods and contain approximately from 0.1 to 100 %, preferably approximately from 1 to 50 %, active constituent. A unit dose for a mammal weighing approximately from 50 to 70 kg may contain approximately from 1 to 500 mg, preferably approximately from 10 to 500 mg, of active constituent.
The following Examples are intended to illustrate the invention and do not represent limitations. The temperatures are in degrees Celsius and all parts are quoted in the form of parts by weight. Unless stated otherwise, all evaporation is carried out under reduced pressure, preferably approximately from 2 to 13 Kilopascal (kPa).
Example 1 : E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester a) 5-(2-propenyl)-oxazoline-4-carboxylic acid ethyl ester (1.) 1.6 g of red copper(I) oxide are introduced into 200 ml of benzene. A solution of 140 g of isocyanoacetic acid ethyl ester and 105 g of freshly distilled methacrolein in 200 ml of benzene is added dropwise to this suspension within a period of 10 minutes with vigorous stirring, during which time the reaction temperature is kept at between 30 and 32° by cooling with ice. When the addition is complete, the mixture is kept at 30-32° until the exothermic reaction subsides, and is then stirred at room temperature for one hour. After excess copper(I) oxide has been filtered off, the filtrate is concentrated by evaporation in vacuo at 30°. 600 ml of ether are added to the residue, which is then filtered over Celite and concentrated to dryness by evaporation in vacuo. In this manner, 5-(2-propenyl)-2-oxazoline-4-carboxylic acid ethyl ester is obtained in the form of a colourless oil having a boiling point of 110-130° (5.3 Pa). b) E-2-formylamino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester (2) 139 g of 5-(2-propenyl)-2-oxazoline-4-carboxylic acid ethyl ester are dissolved in 70 ml of tetrahydrofuran, and 27.4 g of water and 3.5 g of triethylamine are added thereto. The reaction mixture is stirred at 65-70° for 62 hours and, after cooling, is taken up in 200 ml of di-chloromethane. The solution is dried over 200 g of magnesium sulphate, filtered and concentrated by evaporation in vacuo. Purification of the viscous oil which remains by column chromatography (silica gel; hexane/ ethyl acetate 3:2) yields 2-formylamino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester in the form of a diastereoisomeric mixture having a melting point of 67°. c) E-2-formylamino-4-methyl-5-diisopropylphosphono-3-pentenoic acid ethyl ester ( 3 ) Under an argon atmosphere, 18.6 ml of thionyl bromide are added dropwise at 20°, within a period of 5 minutes, to a solution of 40.20 g of crude 2-formylamino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester in 600 ml of 1 , 2-dichloroethane (slight cooling). After stirring for two hours at room temperature, 400 ml of water are added, the first 50 ml being slowly added dropwise. The mixture is stirred thoroughly for a further 15 minutes to complete the reaction. The organic phase is separated off and washed three times with ice-water and once with ice/ saturated potassium bicarbonate solution (pH approximately 7.5). Drying over sodium sulphate and removal of the 1 ,2-dichloroethane by distillation in vacuo at 35° yields the crude bromide as intermediate, to which 160 ml of triisopropyl phosphite are added at room temperature, and the mixture is then stirred at 75° (bath temperature) under a partial vacuum (approximately 13 kPa) for 17 hours. The excess triisopropyl phosphite and other volatile by-products are then distilled off under a high vacuum (bath temperature 90°). Chromatography of the residue on ten times the amount by weight of silica gel (particle size 0.04-0.06 mm) using ethyl acetate as eluant yields E-2-formylamino-4-methyl-5-diisopropylphosphono-3-pentenoic acid ethyl ester in the form of a light-yellow honey, IR (CH2CI2): 3410 (NH); 1740 (CO ester); 1690 (CO amide); 1235 (P=0); 980-1015 (P-0-C). - 28 - d) E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester (4) 56.7 ml of tri ethylbromosilane are added dropwise within a period of 15 minutes at 20° to a solution of 25.42 g of E-2-formylamino-4-methyl-5-diisopropylphosphono-3-pentenoic acid ethyl ester in 102 ml of dry di-chloromethane. After stirring at room temperature for 20 hours, 102 ml of ethanol are added dropwise within a period of 15 minutes, and the whole is stirred for a further 20 hours. The clear reaction solution is then completely concentrated by evaporation in vacuo. The residue is concentrated by evaporation a further three times in each case after the addition of 100 ml of toluene. The oily residue is dissolved in 102 ml of ethanol, and a solution of 102 ml of propylene oxide in 102 ml of ethanol is added dropwise thereto. The product, obtained in crystalline form, is filtered off after 2 hours (room temperature) and washed with ethanol and ether. After drying (80°, 4 hours) under a high vacuum, E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester is obtained in analytically pure form, m.p. 212° (decomp.).
Example 2; E-2-ainino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester a) E-2-formylamino-4-methyl-5-dimethylphosphono-3-pentenoic acid ethyl ester (I) 100.5 g of 2-formylamino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester are dissolved in 1.5 litres of dichloroethane, and then 47 ml of thionyl bromide are added dropwise at 20-25° and the mixture is stirred at room temperature for one hour. 750 ml of water are added to the reaction mixture, which is then stirred vigorously for 10 minutes. The organic phase is separated off, extracted with 1 litre of ice-water, 1 litre of IN potassium hydrogen carbonate solution and a further 1 litre of ice-water, dried over magnesium sulphate and concentrated by evaporation. 50 ml of trimethyl phosphite are added directly to the resulting E-5-bromo-2-formylamino-4-methyl-3-pentenoic acid ethyl ester, a yellow oil, and the mixture is stirred at a bath temperature of 70° and approximately 15 kPa for 15 hours. The reaction mixture is degassed for 30 minutes under a water-jet vacuum and for one hour under a high vacuum at 40-50°. The resulting product is taken up in 600 ml of water and extracted three times with 500 ml of ethyl acetate each time. The - 29 - combined organic phases are washed twice with 300 ml of water each time. All the aqueous phases are combined, saturated with sodium chloride and extracted three times with 500 ml of dichloromethane each time. The combined organic phases are dried over magnesium sulphate and concentrated by evaporation. The product is chromatographed over silica gel (ethyl acetate/isopropanol 7:2). In this manner, E-2-formylamino-4-methyl-5-dimethylphosphono-3-pentenoic acid ethyl ester is obtained in the form of a yellow oil, XH- MR (DMSO): 1.82 (d, 3H, 4-CH3); 2.69 (d, 2H); 5.03 (m, 1H); 5.32 (m, 1H) . b) E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester (2) 16.9 g of E-2-formylamino-4-methyl-5-dimethylphosphono-3-pentenoic acid ethyl ester are dissolved in 80 ml of dichloromethane under a nitrogen atmosphere, and 30 ml of trimethylbromosilane are added dropwise at approximately 25° within a period of 30 minutes. The mixture is stirred at room temperature for 20 hours, and then 80 ml of ethanol are added dropwise at approximately 25° within a period of 30 minutes. The mixture is then again stirred at room temperature for 22 hours and is then concentrated by evaporation. The residue is dissolved in 80 ml of ethanol, and 80 ml of propylene oxide in 80 ml of ethanol are added dropwise with slight cooling. The mixture is stirred at room temperature for one hour to complete the reaction, filtered and washed with ethanol and ether. In this manner there is obtained E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester, m.p. 215-217° (decomp.).
Example 3: E-2-amino-4-tnethyl-5-phosphono-3-pentenoic acid ethyl ester a) E-2-formylamino-4-methyl-5-di(2-chloroethyl)phosphono-3- pentenoic acid ethyl ester (1) 8.2 g of E-5-bromo-2-formylamino-4-methyl-3-pentenoic acid ethyl ester and 19 ml of tris-(2-chloroethyl)-phosphite are stirred at a bath temperature of 70° for 20 hours. The resulting mixture is chromatographed on silica gel using ethyl acetate and ethyl acetate/isopropanol (7:1) as eluant, and the product is crystallised from ethyl acetate/diethyl ether. In this manner there is obtained E-2-formylamino-4-methyl-5-di(2-chloro-ethyl)phosphono-3-pentenoic acid ethyl ester, m.p. 47-49°. b) E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester (2) In a manner analogous to that described in Example 2, using 3 g of E-2-formylamino-4-methyl-5-di(chloroethyl)phosphono-3-pentenoic acid ethyl ester, there is also obtained E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester, m.p. 215° (decomp.).
Example : (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid a) (L)-N-tert .butoxycarbonyl-serine-N-methoxy-N-methyl 541.6 ml of N-methylmorpholine are added within 27 minutes at -20° to -25° to a solution of 1 kg of (L)-N-tert.butoxycarbonyl-serine in 1 litre of tetrahydrofurane . The reaction mixture is stirred for 15 minutes at this temperature. Then 699.6 ml of chloroformic acid iso-butyl ester and subsequently 445,8 ml of N-methoxy-N-methylamine are added within 42 and 40, resp. minutes. The reaction mixture is allowed to warm to room temperature and evaporated to dryness. The residue is dissolved in 3 litres of ethyl acetate. The solution is extracted with 3.5 litres of 2n-hydrochloric acid and subsequently with 3 1 of saturated aqueous sodium hydrogencarbonate solution. The water-layers are extracted with 3 1-litre ethyl acetate. All organic extracts are combined, washed with 2 litres of saturated sodium dichloride solution, dried over magnesium sulfate and evaporated at 50° to dryness. The residue is triturated with 3.5 litres of hexane with ice-cooling. The resulting white precipitate is filtrated off, washed with 1 1 of hexane and dried under reduced pressure to yield 781 g 1_, m.p. 116-117°; calculated for C11H20N2O5 C 48.38 %, H 8.12 % N 11.28 ; found C 48.28 %, H 8.02 %, N 11.32 %. b) (L)-3-tert.butoxycarbonyl-2 , 2-dimethyl-oxazolidine-4-carboxylic acid- N-methoxy-N-methyl-amide (2) A mixture of 781 g of _1, 3.3 litres of acetone dimethylacetal and 42 g of pyridinium(toluol-4-sulfonate) are warmed to 72° and refluxed for 17 hours. After addition of additional 20 g of pyridinium(toluol-4-sulfonate) heating to boil is continued for additional 9 hours while gradually destilling of approximately 750 ml of solvent and adding 700 ml of acetone dimethylacetal. All volatile constituents we destilled off. The residue is dessolved in 2 litres of diethyl ether and extracted twice with 1 litre and 0.5 litre of n-hydrochloric acid, once with 0.3 litre of saturated sodium hydrogencarbonate solution and once with 0.3 litre of saturated sodium chloride solution. The aqueous extracts we re-extracted twice with 0.5 litre either time of diethyl ether. All organic extracts are combined, dried over magnesium sulfate and evaporated to dryness. The residue is dissolved hot in a 9:l-mixture of hexane and diethyl ether. After addition of additional 600 ml of hexane and 50 ml of diethyl ether, the reaction mixture is cooled down while diluting a crystallisation with 1.1 litre of hexane. The precipitate formed is filtered off, washed with hexane and dried under reduced pressure at 40° yielding 640 g of 2; m.p. 67-68°; calculated for C13H21(N205 C 54.15 %, H 8.39 %, N 9.72 %; found C 53.96 %, H 8.37 %, N 9.91 %. c) (4S)-2,2-dimethyl-4-formyl-3-oxazolidine-carboxylic acid tert. butyl ester (3) 2.53 g of lithium aluminium hydride are added with cooling to maintain a temperature of 5 to 15° to 28.8 g of 2, dissolved in 350 ml of diethyl ether. After stirring at 5° for 1.5 hours a solution of 5.77 g of sodium hydrogen sulfate is added slowly to keep the reaction temperature at 15° (40 minutes). The suspensions formed is filtered clear and the solid portion is washed with ether. The filtrate is washed, with cooling, twice with 200 ml each of n-hydrochloric acid, twice with 150 ml each of 5 % sodium hydrogencarbonate solution and dried with 100 ml of saturated sodium chloride solution. The aqueous extracts are re-extracted with ether and all organic extracts are combined, dried over sodium sulfate and evaporated. The residue is distilled at 0.4 ml yielding 17.78 g of 3; b.p. 85-90°, [ot]D ■ -94 (c=l, CHC13); calculated for CnHigNOu C 57.63 %, H 8.35 % N 6.11 %, 0 27.91 %; found C 57.59 %, H 8.54 %, N 6.17 %, 0 27.74 %. d) 3-( ( 4 ' R)-N-tert . -butoxycarbonyl-2 ' , 2 '-dimeth 1-4 ' -oxazolidlny1)-2- methylpropenoic acid ethyl ester (4) A solution of 39.5 g of (4S)-2,2-dimethyl-4-formyl-3-oxazolidinecarbo-xylic acid tert.-butyl ester 3 in 200 ml of dichloromethane is added dropwise within a period of 2 hours to a solution of 68.7 g of 1-ethoxy-carbonylethylidenetriphenylphosphorane in 900 ml of dichloromethane.
After stirring at room temperature for 6 hours, the mixture is cooled to 10° and there are then added dropwise within a period of 15 minutes 530 ml of a 10 % aqueous sodium hydrogen phosphate solution. After stirring at 15° for 30 minutes, the organic phase is separated off and the aqueous phase is extracted with 250 ml of dichloromethane. The organic phases are dried over magnesium sulphate and concentrated by evaporation. The residue is stirred with 70 ml of ether. The suspension is filtered and the filtration residue is washed with ether. The filtrate is concentrated by evaporation and the residue is separated by chromatography on silica gel. Elution with hexane/ethyl acetate 9:1 yields, in addition to 2.32 g of cis-isomer and 2.21 g of mixed fraction (cis/trans » 38:62), 45.4 g of 4. 1 H-NMR (60 MHz, CDC13, trans-isomer): inter alia 4.7 ppm (m, H-C(4')); 6.7 ppm (d, J=9, H-C(3)). 1 H-NMR (60 MHz, CDCI3, cis-isomer): inter alia 5.2 ppm (m H-C(4')); 6.08 ppm (d, J=7, H-C(3)). e) ( R)-2 , 2-dimethyl-4-( 3 ' -hydroxy-2 ' -methylprop-1 ' -enyl)-oxazolidine-3- carboxylic acid tert. -butyl ester (5) 389 ml of a 1 molar solution of diisobutylaluminium hydride in hexane are added within a period of 15 minutes to a solution, cooled to 3°, of 48.7 g of 4 in 1 litre of dry diethyl ether. The temperature of the mixture is allowed to rise to 11°, and there are then added thereto, while cooling with ice, 100 ml of ethyl acetate followed by 50 ml of 2N sodium hydroxide solution. The temperature of the mixture is allowed to rise to approximately 28°, without cooling, and then a further 7 ml of 2N sodium hydroxide solution are added. The mixture is stirred at room temperature for 15 hours, and then sodium sulphate is added and the whole is filtered. Concentration of the filtrate by evaporation yields 42.1 g of crude 2. A sample (0.97 g) is purified by chromatography on 40 g of silica gel. Elution with hexane/ethyl acetate 3:1 yields 0.74 g of 5. 1 H-NMR (300 MHz, DMS0-d6): inter alia 3.52 (dxd, J=9 and 3) and 4.02 (dxd, J=9 and 6) (2H-C(5)); 3.78 (m, 2H-C(3')); 4.54 (m, H-C(4)); 4.81 (t, J=6, OH); 5.33 (d, J=9, H-C(l')). f) ( 4R)-2 , 2-dimethyl-4-( 3 ' -bromo-2 ' -methylprop-1 ' -enyl)-oxazolidine-3- carboxylic acid tert. -butyl ester (6) 47.6 g of triphenylphosphine are added at 0° to a solution of 41.0 g of 5 and 60.2 g of tetrabromomethane in 1 litre of dry diethyl ether. After 30 minutes, the cooling bath is removed and the mixture is stirred at room temperature for 17 hours. 20 g of tetrabromomethane and 15.9 g of triphenylphosphine are added, and the mixture is stirred at room temperature for 2 hours. The white suspension is filtered and the filtration residue is washed with ether. The residue remaining after the filtrate has been concentrated by evaporation is chromatographed on 0.9 kg of silica gel. Elution with hexane/ethyl acetate 9:1 yields 30.59 g of j6, m.p. 62-65°C. 1 H-NMR (300 MHz, DMS0-d6): inter alia 3.55 (dxd, J=9 and 2) and 4.04 (dxd, J«=9 and 6) (2H-C(5)); 4.15 (m, 2H-C(3')); 4.49 (m, H-C(4)); 5.65 (d, J=9, H-C(l')). g) ( R)-2 , 2-dimethyl-4-( 3 ' -dimeth lphosphono-2 '-methylprop-1 '-enyl)-oxa- zolidine-3-carboxylic acid tert. -butyl ester ( ) A solution of 13.4 g of 6 in 70 ml of trimethyl phosphite is stirred at 80° for 15 hours. The excess phosphite is evaporated off at 24 bar.
Drying of the residue under a high vacuum yields 14.3 g of crude 7. 1 H-NMR (300 MHz, DMS0-d6): inter alia 2.63 (d, J=23, 2H-C(3')); 3.59 (d, J=ll, (CH30)2PO). h) N-((2R)-5-dimethylphosphono-l-hydroxy-4-methyl-3-penten- 2-yl)- carbamic acid tert.-butyl ester (8) 7 g of Amberlyst® 15 (H+ form, 20-50 mesh) are added to a solution of 14.0 g of 2 I 250 ml of methanol. The mixture is stirred at room temperature for 17 hours and filtered, and the filtrate is concentrated by evaporation. Chromatography of the residue on 0.33 kg of silica gel using ethyl acetate/methanol 10:1 as eluant yields 10.6 g of 8. ^- MR (300 MHz, DMSO-de): inter alia 4.60 (t, J«6, OH); 6.67 (d, J=7, NH) . i) (2R)-2-tert .-butoxycarbonylamino-5-dimethylphosphono-4- methyl-3- pentenoic acid (9) i,a) Oxidation with chromosulphuric acid To a solution of 0.323 g of 8 in 10 ml of acetone there is added 0.77 ml of a solution that is 3.25 molar in chromium trioxide and 5.29 molar in sulphuric acid. The mixture is stirred at room temperature for 40 minutes and then there are added 2 ml of isopropanol followed by 50 ml of ethyl acetate. 0.1 g of active carbon is then added to the mixture. After 10 minutes, the mixture is filtered and washed with 50 ml of ethyl acetate. The filtrate is extracted three times with 50 ml of 10 % sodium hydrogen carbonate solution each time. The aqueous phase is extracted twice with 40 ml of ethyl acetate each time, acidified to pH 1 using 2N hydrochloric acid, and then extracted three times with 70 ml of ethyl acetate each time. The organic extracts are washed with saturated sodium chloride solution, dried over magnesium sulphate and concentrated by evaporation. Chromatography on 8 g of silica gel using chloroform/ ethanol/acetic acid 18:1:1 as eluant yields 65 mg of 9. 'H-NMR (300 MHz, DMSO-de): 1.37 (s, (CH3)3CO); 1.82 (d, J»2, CH3-C(4)); 2.63 (d, J«22, 2H-C(5)); 3.61 (d, J-ll, (CH30)2P0); 4.62 (t, J=8, H-C(2)); 5.25 (m, H-C(3)); 7.18 (d, J»8, NH); 11.7-12.5 (C02H). i,b) Oxidation with oxygen/platinum To a solution of 0.66 g of 8 and 0.2 g of sodium hydrogen carbonate in 20 ml of water and 2 ml of dioxan there is added a suspension of platinum prepared by hydrogenation of 313 mg of platinum oxide in 50 ml of water. In a cylindrical apparatus, oxygen is passed through the mixture from bottom to top at 55° by means of a glass frit, with vigorous stirring. The mixture is filtered and washed with water, and the filtrate is extracted five times with 100-150 ml of ethyl acetate each time. Concentration of the extracts by evaporation yields 220 mg of educt 5. 1 g of Amberlyst® 15 (strongly acidic) is added to the aqueous phase, which is then filtered and concentrated by evaporation in vacuo at 40°. Purification as in f,a) yields 156 mg of 9. 1H-NMR (300 MHz, CDC13): 1.43 (s, (CH3)3C); 1.96 (d, J=3 Hz, CH3-C(4)); 2.55 and 2.71 (2 dxd, J=22 and 15, 2H-C(5)); 3.75 and 3.76 (2 d, J=ll, 2 OCH3) 4.97 (m, H-C(2)); 5.25-5.45 (m, NH and H-C(3)). j) (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (10) 0.71 ml of trimethylsilyl bromide is added at 0° to a solution of 123 mg of 9 in 3 ml of dichloromethane . After stirring at 0° for 4 hours, 20 ml of water are added. After 30 minutes, the dichloromethane phase is separated off and washed three times with 15 ml of water each time. The aqueous phases are extracted three times with 20 ml of dichloromethane each time and concentrated by evaporation in vacuo. The residue is dissolved in 10 ml of 5N hydrochloric acid and is then stirred for 48 hours, diluted with 20 ml of water and extracted three times with 20 ml of dichloromethane each time. The aqueous phase is concentrated by evaporation in vacuo, and the residue is dried under a high vacuum and dissolved in 3 ml of ethanol, and then approximately 1 ml of propylene oxide is added dropwise thereto. The suspension is filtered. Washing of the filtration residue with ethanol and drying under a high vacuum at room temperature yields 62 mg of 1 , m.p. 165°C (decomposition).
In order to analyse the purity of the enantiomer, a sample is derivatised to the amide with (R)-(+)-methoxytrifluoromethylphenylacetic acid chloride. 1 H-NMR analysis (300 MHz) by integration of the 0CH3 signals gives ≥ 95 % (2R)-isomer (3.44 ppm) and ≤ 5 % (2S)-isomer (3.37 ppm) .
Example 5: (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester a) (4R)-2 , 2-dimethyl-4-( 3'-diisopropylphosphono-2 '-methyl- prop-1 ' -enyl)- oxazolidine-3-carboxylic acid tert. -butyl ester O) A solution of 6.68 g of bromide according to Example 5f in 14.8 ml of dry triisopropyl phosphite is heated at 70°C for 17 hours under a pressure of 100 mbar. The mixture is concentrated by evaporation at 0.4 mbar/ 70°. Chromatography on 350 g of silica gel (eluant hexane/ ethyl acetate 1:1) yields 8.28 g of 1, Rf value « 0.077. b) N-( (2R)-5-diisopropylphosphono-l-hydroxy-4-methyl-3-penten-2-yl)- carbamic acid tert. -butyl ester (2) 2.25 g of Amberlyst® 15 (H form, 20-50 mesh) are added to a solution of 4.49 g of phosphonic acid ester 1 according to a) in 100 ml of methanol. The mixture is stirred at room temperature for 2 days and is filtered, and the filtrate is concentrated by evaporation. Chromatography of the residue on 125 g of silica gel (eluant ethyl acetate /methanol 20:1) yields 2.44 g of 2. c) ( 2R)-2-tert . -butoxycarbonylamino-5-diisopropylphosphono-4-methyl-3- pentenoic acid (3) To a solution of 1.6 g of alcohol 2 according to b) in 60 ml of acetone there are added at 0-5° 3.3 ml of a solution that is 3.25 molar in chromium(VI) oxide and 5.29 molar in sulphuric acid. The mixture is stirred at 0° for 6 hours and at room temperature for 12 hours. After the addition of 5 ml of isopropanol and 40 ml of 20 % sodium chloride solution, the mixture is stirred for 10 minutes and is then extracted continuously with methyl acetate for 15 hours in a Kutscher-Steudel apparatus. The organic phase is dried over sodium sulphate and concentrated by evaporation, and the residue is chromatographed on 75 g of hexane/ethyl acetate/acetic acid 16:10:1. This yields 0.92 g of 3, [α)β --94.5° (c - 1.2, CHC13). lH- MR (300 MHz, CDC13 ) : 1.2-1.3 (4d, (2-propO)2); 1.4 (s, (CH3).C0); 1.95 (d, J=3, CH3-C(4)); 3.5 and 3.62 (2 dxd, J»23 and 15, 2H-C(5)); 4.66 (m, (2-propO)2); 4.92 (m, H-C(2)); 5.30 (m, H-C(3)); 5.42 (d, J-7, H) ; 9.0-10.0 (broad, C02H). d) (2R)-2-tert.-butoxycarbonylamino-5-diisopropylphosphono-4-methyl-3- pentenoic acid ethyl ester (4) 0.09 g of l-amino-l-chloro-N,N,2-trimethylpropene is added at 0-5° to a solution of 0.2 g of acid 3 according to c) in 15 ml of dry dichloro-methane. After stirring for 30 minutes at 0°, 0.4 g of pyridine in 5 ml of ethanol is added. The mixture is stirred further at 0° for 90 minutes and at room temperature for 15 hours, and is then diluted with 20 ml of dichloromethane and washed twice with 20 ml of water each time. The organic phase is dried using sodium sulphate, concentrated by evaporation and chromatographed on 25 g of silica gel. Elution with ethyl acetate/ methanol 10:1 yields 0.12 g of 4. 1 H-NMR (300 MHz, CDCl3): 1.2-1. A (m, 2 (CH3)2CHO, CH3CH2O) ; 1.45 (s, (CH3)3CO); 1.98 (d, J=3, CH3-C(4)); 2.55 (d, J=23, 2H-C(5)); 4.2 (m, CH3CH2.O); 4.69 (m, 2 (CH3)2CHO) ; 5.0 (m, H-C(2)); 5.16 (m, H-C( 3) , NH) . e) (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester (5) 0.11 ml of trimethylsilyl bromide is added at 0° to a solution of 0.1 g of ester 4 according to d) in 10 ml of dichloromethane. The mixture is stirred at 0° for 4 hours and at room temperature for 15 hours. 20 ml of water are added, the mixture is stirred for 15 minutes, and then the aqueous phase is separated off and the water is evaporated off under a high vacuum. The residue is dissolved twice in 5 ml of ethanol each time, concentrated by evaporation and again dissolved in 5 ml of ethanol. 0.5 ml of propylene oxide is added. The precipitate is filtered off, washed with ethanol and dried under a high vacuum for 15 hours; 48 mg of 5, [a]D = -75° (c=0.5, H20).
In order to analyse the purity of the enantiomer, a sample is derivatised to the amide dimethyl ester with (R)-(+)-methoxytrifluoromethylphenyl-acetic acid chloride followed by diazomethane . 1 H-NMR analysis (300 MHz) by integration of the 0CH3 signals gives > 97 % (2R)-isomer (3.5 ppm) and < 3 % (2S)-isomer (3.37 ppm).
Example 6 : (2R)-2-amino-4-methyl-7-phosphono-3-heptenoic acid (10) a) (4R)-2 , 2-dimethyl-4-( 1 ' -hydroxy-2 ' -methylprop-2 ' -enyl)-oxazolidine- 3-carboxylic acid tert. -butyl ester O) 45 ml of a 1.1 molar solution of isopropenylmagnesium bromide are added dropwise at 0-5° within a period of 25 minutes to a solution of 6.9 g of (4S)-2,2-dimethyl-4-formyloxazolidine-3-carboxylic acid tert. -butyl ester (according to Example 5c)) in 60 ml of dry tetrahydrofuran. The mixture is stirred at 0° for 45 minutes, allowed to warm up to room temperature and cooled again to 10°, and then 90 ml of buffer solution (1 molar, phosphate, pH 7) are added. The mixture is filtered and the filtrate is extracted twice with 100 ml of ethyl acetate each time. The organic phase is washed twice with 50 ml of water each time and with saturated sodium chloride solution, and is dried with sodium sulphate. Removal of the solvent by evaporation yields 8 g of 1_, a diastereoisomeric mixture.
Separation may be effected by chromatography on silica gel using hexane/ ethyl acetate 4:1 and yields crystalline ( 1 ' S)-threo-epimer (R^ value: 0.2) and (1 'R)-erythro-epimer (R^ value: 0.16) in a ratio of approximately 1:2. b) ( 4R)-4-( 1 ' -acetoxy-2 ' -methylprop-2 *-eny1)-2 , 2-dimethy1-oxazolidine- 3-carboxylic acid tert. -butyl ester (2) 60 ml of acetic anhydride are added dropwise at 0-5° within a period of 10 minutes to a solution of 15.6 g of the epimer mixture according to a) in 60 ml of pyridine. The mixture is stirred at room temperature for 15 hours and diluted with 0.5 litre of diethyl ether, and then 200 ml of 2N hydrochloric acid are added while cooling with ice. The organic phase is washed with 250 ml of 2N hydrochloric acid and twice with 200 ml of 10 % sodium carbonate solution each time. Drying over sodium sulphate and removal of the solvent by evaporation yields 15.4 g of 2. c) (4R)-4-(4'-carboxy-2' -methylbutenyl)-2 ,2-dimethyl-oxazolidine-3- carboxylic acid tert. -butyl ester (3) 34.5 ml of a 1.6 molar solution of butyllithium in hexane are added at 0° to a solution of 5.25 g of diisopropylamine in 200 ml of dry tetrahydro-furan. The mixture is cooled to -75°C and a solution of 15 g of acetate 2 according to b) in 100 ml of tetrahydrofuran is added dropwise within a period of 10 minutes, and after 5 minutes a solution of 8 g of tert.-butyldimethylsilyl chloride in 30 ml of 1 , 3-dimethyl-3,4,5,6-tetrahydro-2-(lH)-pyrimidinone is added. The mixture is allowed to warm up to room temperature and is then heated under reflux for 2 hours and cooled to room temperature. 230 ml of 45 % ammonium fluoride solution are added, and the whole is stirred at room temperature for 20 hours and is then concentrated by evaporation. 150 ml of IN sodium hydroxide solution are added, while cooling with ice, to the oily residue which is obtained after concentration of the organic phase by evaporation, and the mixture is extracted twice with 200 ml of dichloromethane each time. The aqueous phase is acidified with 300 ml of 20 % citric acid solution and is extracted three times with 300 ml of dichloromethane each time. The organic phases are washed with 20 % sodium chloride solution, dried over sodium sulphate and concentrated by evaporation. Chromatography of the residue on 50 g of silica gel using hexane/ethyl acetate 1:1 as eluant yields 11 g of solid 3. d) ( 4R)-4-( ' -carbaethoxy-2 ' -methylbutenyl)-2 , 2-dimethyl-oxazolidine-3- carboxylic acid tert. -butyl ester (4) d,a) Starting from the acid 3 3.9 ml of l-amino-l-chloro-N,N, 2-trimethylpropene are added dropwise within a period of 10 minutes to an ice-cooled solution of 7.8 g of carboxylic acid 3 according to c) in 100 ml of dry dichloromethane. After 30 minutes at 0°, a solution of 2.2 g of pyridine in 80 ml of ethanol is added within a period of 20 minutes. After stirring at room temperature for 12 hours, the mixture is diluted with 100 ml of dichloromethane and washed twice with 100 ml of water each time. The organic phase is dried over sodium sulphate and concentrated by evaporation. Chromatography of the residue on silica gel using hexane/ethyl acetate 10:1 yields 6.5 g of ester 4, [a]D = +6.17° (c-1, CHC13). Ci8H3iN05, calculated: C 63.32 %, H 9.15 %, N 4.10 %; found: C 63.4 , H 9.2 %, N 4.5 %. d,b) Starting from the epimer mixture 1 A solution of 8 g of alcohol l^ according to a) and 0.05 ml of propionic acid in 10.5 ml of orthoacetic acid triethyl ester is heated at 135-140° for 14 hours, with ethanol slowly being distilled off. The whole is concentrated by evaporation at 40° under a high vacuum. Chromatography of the residue on silica gel using hexane/ethyl acetate 10:1 yields 8 g of 4. e) ( 4R)-2 , 2-dimethyl-4-( 5 ' -hydroxy-2 ' -methylpent-11 -enyl)-oxazolidine- 3-carboxylic acid tert. -butyl ester (5) 1.61 g of lithium aluminium hydride are added in portions at 0° to a solution of 14.5 g of 4 according to d) in 250 ml of absolute diethyl ether. The mixture is stirred at 0-2° for 18 hours, and a solution of 5 g of potassium hydrogen sulphate in 60 ml of water is added while cooling with acetone/dry ice. The mixture is filtered and washed four times with 200 ml of diethyl ether each time. The organic phase is washed three times with 80 ml of IN hydrochloric acid each time, three times with 80 ml of saturated sodium bicarbonate solution each time, and twice with 200 ml of saturated sodium chloride solution each time, and is then dried over sodium sulphate and concentrated by evaporation. Chromatography on silica gel using hexane/ethyl acetate 1:1 yields 11.3 g of 5, Ci6H2g Oi,, calculated: C 64.19 %, H 9.77 %, N 4.68 %; found: C 63.6 %, H 9.8 %, N 4.7 %. f) ( 4R)-4-( 5 ' -bromo-2 ' -methylpent-1 * -enyl)-2 , 2-dimethyl-oxazolidine-3- carboxylic acid tert. -butyl ester (6) 4.87 g of tetrabromomethane, 3.85 g of triphenylphosphine and 0.6 ml of pyridine are added at 0-2° to a solution of 4.4 g of alcohol 5 according to e) in 200 ml of dichloromethane. After 12 hours at 0-2°, a further 1 g of tetrabromomethane and 1 g of triphenylphosphine are added and the mixture is stirred at 0° for 6 hours. The mixture is concentrated by evaporation, taken up in ethyl acetate, filtered and concentrated.
Chromatography on silica gel using hexane/ethyl acetate 10:1 yields 4.5 g of 6, Ci6H28N03Br; calculated: C 53.04 , H 7.79 %, N 3.87 , Br 22.06 %; found: C 53.1 %, H 7.7 %, N 3.9 %,-Br 21.6 %. g) ( 4R)-2 , 2-dimethyl-4-( 2 ' -methyl-5' -diisoprop lphosphono-pent-1 ' -enyl)- oxazolidine-3-carboxylic acid tert. -butyl ester (]_) A solution of 10.9 g of bromide 6 in 22 ml of triisopropyl phosphite is heated at 135-140° for 24 hours at 100 mbar. The excess reagent is evaporated off at 0.1 mbar/60°. Chromatography of the residue on silica gel using hexane/ethyl acetate 1:1 yields 10.7 g of · h) N-( (2R)-l-hydroxy-4-methyl-7-diisopropylphosphonohept-3- en-2-yl)- carbamic acid tert. -butyl ester (8) 3 g of Amberlyst® 15 (H form) are added to a solution of 3 g of 2 according to g) in 100 ml of ethanol. The mixture is stirred at room temperature for 20 hours, filtered, concentrated by evaporation and chromatographed on 50 g of silica gel. Elution with ethyl acetate/ methanol 10:1 yields 2.3 g of 8, [o]D - -5.9° (c-1, CHCI3 ) . CigH38 06P; calculated: C 56.0 %, H 9.4 %, N 3.44 %, P 7.6 %; found: C 55.4 %, H 9.3 %, N 3.4 %, P 7.3 %. i) (2R)-2-tert .-butoxycarbonylamino-4-methyl-7-diisopropylphosphono-3- heptenoic acid (9) i,a) Oxidation with chromic acid 0.84 ml of a solution which is 3.25 molar in chromium trioxide and 5.29 molar in sulphuric acid is added dropwise at 0-5° to a solution of 0.5 g of alcohol 8 according to h) in 15 ml of acetone. The mixture is stirred at 0° for 30 minutes and at room temperature for 35 minutes, and then 4 ml of isopropanol, 80 ml of ethyl acetate and 30 ml of 20 % sodium chloride solution are added thereto, and the mixture is filtered. The aqueous phase is extracted three times with 20 ml of ethyl acetate each time. The organic phase is dried over sodium sulphate and concentrated by evaporation. Chromatography on 20 g of silica gel using hexane/ethyl acetate/acetic acid 16:10:1 yields 0.34 g of 9, [α]β = -35.25° (c=1.39, CHCI3), 1 * C-NMR (75 MHz, CDCI3) : 173.8 (C02H); 155.0 (OCON); 140.4 (C(4)) 121.1 (C(3)); 79.5 (0C(CH3)3); 70.3 (OCH); 52.1 (C(2)); 39.7 (d, J=18, C(5)); 28.3 ((CH3)3C); 25.7 (d, J=142, C(7)); 24.0 ((CHa CH); 20.2 (d, J»5, C(6)). 1,b) Oxidation with platinum/oxygen To a solution of 3 g of alcohol 8 according to h) in 105 ml of dioxan there is added at 55° a suspension of platinum in 45 ml of water prepared by hydrogenation and degassing of 1 g of platinum oxide in 45 ml of water. Oxygen is passed through the mixture at 55-60° with vigorous stirring (approximately 1900 rpm) . The mixture is filtered through Celite® and washed twice with 80 ml of water each time, and the filtrate is concentrated by evaporation at 40° under a high vacuum. The resulting product is dissolved in 200 ml of water, and 1 g of sodium bicarbonate and 50 ml of 20 % sodium chloride solution are added and the mixture is extracted three times with 100 ml of ethyl acetate each time. The organic phases are dried over sodium sulphate. Filtration and concentration by evaporation yield 1.8 g of educt 8. The aqueous phase is acidified with approximately 20 ml of IN sulphuric acid and extracted five times with 120 ml of ethyl acetate each time. Drying over sodium sulphate, concentration by evaporation and chromatography of the residue according to i,a) yield 0.8 g of acid 9. j) (2R)-2-amino-4-methyl-7-phosphono-3-heptenoic acid (10) A solution of 3.3 g of acid 9 according to i) and 2.6 g of N,0-bis-tri-methylsilylacetamide is stirred at room temperature for one hour under argon. After the addition of 4.4 g of trimethylbromosilane, the mixture is stirred for 24 hours. The reaction mixture is added dropwise at 0° to 400 ml of water, and the whole is stirred for 30 minutes. The organic phase is separated off and washed three times with 50 ml of water each time. The aqueous phases are extracted three times with 30 ml of di-chloromethane each time and concentrated to 10 ml at 40° under a high vacuum. Chromatography on 20 ml of Dowex® 50 Wx8 using water as eluant, and lyophilisation of the eluate yield 0.4 g of 10 in the form of an amorphous white powder having a melting point of 252° (decomposition); (a]D = -86.5° (c-1, H20); C8Hi6N05P.l H20; calculated: C 37.05 %, H 6.9 %, N 5.5 %; found: C 36.3 %, H 6.5 %, N 5.6 %.
In order to analyse the purity of the enantiomer, a sample is derivatised to the amide with (R)-(+)-methoxytrifluoromethylphenylacetic acid chloride. *H-NMR analysis (300 MHz) by integration of the 0CH3 signals gives ≥ 94 % (2R)-isomer (3.24 ppm) and ≤ 6 % (2S)-isomer (3.17 ppm) .
Example 7 ; ( 2R)-2-amino-7-phosphono-3-heptenoic acid a) (4R)-2 , 2-dimethyl-4-( 1 ' -hydroxyprop-2 ' -enyl)-oxazol-idine-3-carboxylic acid tert. -butyl ester (1_) 60 ml of a 2.4M solution of vinylmagnesium bromide in tetrahydrofuran are added at 0-5° within a period of 30 minutes to a solution of 25 g of (4S)-2 , 2-dimethyl-4-formyloxazolidine-3-carboxylic acid tert. -butyl ester (according to Example 5c) in 300 ml of dry tetrahydrofuran. The mixture is stirred at 0° for one hour, allowed to warm up to room temperature and then stirred at room temperature for a further one hour. 300 ml of buffer solution (1 molar, phosphate, pH 7) are added while cooling to 10°. After 10 minutes, the mixture is filtered, extracted twice with 150 ml of ethyl acetate each time and washed twice with 100 ml of water each time. The aqueous phase is extracted twice with 100 ml of ethyl acetate each time. The organic extracts are dried over sodium sulphate and concentrated by evaporation. Chromatography of the residue on silica gel using hexane/ ethyl acetate 4:1 yields 24.2 g of epimer mixture 1_; C13H23NO1,; calculated: C 60.68 %, H 9.01 %, N 5.44 %; found: C 60.7 %, H 9.1 %, N 5.6 %. b) ( 4R)-4-( 4 ' -ethoxycarbonylbutenyl)-2 , 2-dimethyloxazolidine-3- carboxylic acid tert. -butyl ester (2) A solution of 22.5 g of alcohol 1_ according to a) and 0.3 ml of propionic acid in 38.5 ml of orthoformic acid triethyl ester is heated at 135-140°C for 4 hours, with ethanol slowly being distilled off. The mixture is concentrated by evaporation at 50° under a high vacuum and chromato-graphed on 300 g of silica gel. Elution with hexane/ethyl acetate 4:1 yields 23.9 g of 2, [o]D = -10.0° (c=1.5, CHCl 3 ) ; C17H29N05; calculated: C 62.36 %, H 8.93 %, N 4.28 %; found: C 62.2 %, H 8.9 %, N 4.4 %. c) ( R)-2 , 2-dimethyl-4-( 5' -hydroxypentenyl)-oxazolidine-3-carboxylic acid tert. -butyl ester (3) 2.7 g of lithium aluminium hydride are added in portions at 0-2° to a solution of 23.5 g of 2 according to b) in 550 ml of absolute diethyl ether. After stirring at 0-2° for 3 hours, a solution of 25 g of potassium hydrogen sulphate in 250 ml of water is added dropwise with cooling. The mixture is filtered through Celite® and washed thoroughly with diethyl ether. The organic phase is washed twice with 200 ml of IN hydrochloric acid each time and twice with 250 ml of 10 % sodium bicarbonate solution each time. The aqueous phases are extracted twice with 100 ml of ether each time. The organic phases are washed with 20 % sodium chloride solution, dried over sodium sulphate and concentrated by evaporation. Chromatography on silica gel using hexane/ethyl acetate as eluant yields 18.6 g of 3, [a]D = -10.1° (c=1.4, CHC13 ) ; CisHzy Oi,; calculated: 63.13 %, H 9.54 %, N 4.91 %; found: C 63.0 %, H 9.5 %, N 5.0 %. d) (4R)-4-( 5' -bromopentenyl)-2 , 2-dimethyloxazolidine-3-carboxylic acid tert. -butyl ester (4) 7 ml of pyridine are added dropwise at 0° to a solution of 18.5 g of alcohol 3 according to c), 28.2 g of tetrabromomethane and 22.3 g of triphenylphosphine in 600 ml of dichloromethane. The mixture is stirred at 0-2° for 12 hours, concentrated by evaporation, taken up in 150 ml of ethyl acetate, filtered, concentrated to 50 ml and chromatographed on 200 g of silica gel. Elution with hexane/ethyl acetate 10:1 yields 19.9 g of bromide 4, [ct]D » -18.9° (c=l, CHCI3 ) ; Ci5H26 03Br; calculated: C 51.73 ¾, H 7.53 %, N 4.02 %, Br 22.94 %; found: C 51.7 %, H 7.7 %, N 4.2 ¾, Br 23.0 %. e) (4R)-2 , 2-dimethyl-4-(5'-di-2-propylphosphonopentenyl)-oxazolidine-3- carboxylic acid tert. -butyl ester (5) A solution of 19.9 g of bromide 4 according to d) in 60 ml of triiso-propyl phosphite is heated at 130-135° for 20 hours at 100 mbar. The excess reagent is distilled off at 60°/0.1 mbar, and the residue is chromatographed on 250 g of silica gel. Elution with hexane/ethyl acetate 1:1 yields 20.6 g of phosphonic acid ester 5, β -8.6° (c=0.8, CHCI3); C2iHi»oN06P; calculated: C 58.18 , H 9.30 %, N 3.23 %, P 7.15 ; found: C 57.4 %, H 9.3 %, N 3.2 %, P 7.5 . f) N-( ( 2R)-l-hydroxy-7-(diisopropylphosphonohept-3-en-2-yl)-carbamic acid tert. -butyl eater (6) A solution of 20.6 g of 5 according to e) in 800 ml of methanol is stirred at room temperature for 20 hours with 30 g of Amberlyst® 15 (H+ form). The mixture is filtered, washed with methanol, concentrated by evaporation and chromatographed on 100 g of silica gel. Elution with ethyl acetate yields 14.8 g of 6, [a}^ ■ -3.6° (c=1.5, CHC13); CiaHaeNOeP calculated: C 54.95 ¾, H 9.22 %, N 3.56 %, P 7.87 %; found: C 53.6 %, H 9.0 %, N 3.4 %, P 9.0 %. g) (2R)-2-tert .-butoxycarbonylamino-7-diisopropylphosphono- 3-heptenoic acid (7) To a solution of 7.4 g of alcohol 6 according to f) in 300 ml of acetone there are added dropwise at 0-2°C, within a period of 20 minutes, 15 ml of a solution which is 3.25 molar in chromium trioxide and 5.29 molar in sulphuric acid. The mixture is stirred at 0-2° for 2 hours and at room temperature for 4 hours, and then 30 ml of isopropanol, 300 ml of ethyl acetate and 200 ml of 20 % sodium chloride solution are added. The aqueous phase is extracted three times with 250 ml of ethyl acetate each time, and the organic phases are dried over sodium sulphate and concentrated by evaporation. Chromatography on 200 g of silica gel using hexane/ethyl acetate/acetic acid 16:10:1 yields 4.55 g of acid 2» ("JQ " -24.9° (c«=0.8, CHCI3) . h) (2R)-2-amino-7-phosphono-3-heptenoic acid (8) A solution of 3.1 g of acid T_ and 3 ml of Ν,Ο-bis-trimethylsilylacetamide in 200 ml of dry dichloromethane is stirred at room temperature for one hour. 3.5 ml of trimethylbromosilane are added, and the mixture is stirred at room temperature for 30 hours. The volatile portions are evaporated off, the residue is taken up in 50 ml of dichloromethane, and 250 ml of water are added at 0-2°. The aqueous phase is separated off and concentrated to 10 ml under a high vacuum. Chromatography on 20 ml of Dowex® 50 x8 using water as eluant, and lyophilisation of the eluate yield 1.04 g of 8 in the form of an amorphous powder, = -65.2° (c=l H20); 13C-NMR (75 MHz, Dz0): 172.8 (C02H); 140.3 (C(4)); 122.2 (C(3)); 56.4 (C(2)); 33.3 (d, J=17, C(5)); 27.3 (d, J=134, C(7)) 22.6 (d, J=4, C(6)). In order to analyse the purity of the enantiomer, a sample is derivatised to the amide trimethyl ester with (R)-(+)-methoxytrifluoro-methylphenylacetic acid chloride followed by diazomethane. 1 H-NMR analysis (300 MHz) by integration of the OCH3 signals gives > 95 % (2R)-isomer (3.54 ppm) and < 5 % (2S)-isomer (3.37 ppm) .
Example 8; (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester a) (2R, 3S)-2-formylamino-3-hydroxy-4-raethyl-4-pentenoic acid ethyl ester Q) aa) Starting from 1 , 1 , 3, 3-tetramethyl-l , 3-disila-2-azolidine-N-acetic acid ethyl ester 7.6 ml of a 1.6 molar solution of butyllithium in hexane are added at -20° to a solution of 2.26 ml of N-cyclohexyl-N-isopropylamine in 60 ml of absolute tetrahydrofuran. After 20 minutes, the mixture is cooled to -78° and there is added dropwise a solution of 3 g of 1 , 1 , 3, 3-tetramethyl-l , 3-disila-2-azolidine-N-acetic acid ethyl ester in 60 ml of tetrahydrofuran. The mixture is stirred at -78° for one hour, and then 142 ml of an approximately 0.035 molar solution of cyclopentadienyl-bis-0-1 , 2 : 5, 6-diisopropylidene-D-glucofuranosyltitanium( IV) chloride in ethe are added and the mixture is stirred at -78° for 17 hours. The reaction solution is transferred via a small steel tube, by argon pressure, into vessel containing a solution, cooled to -78°, of 1.1 ml of methacrolein in 15 ml of tetrahydrofuran. The whole is allowed to warm up slowly to room temperature, and is then stirred for 2 hours. 1.5 ml of water are added, and the mixture is filtered. The filtrate is diluted with 250 ml of diethyl ether, and is then washed three times with 250 ml of approximately 10 % sodium chloride solution each time and with 250 ml of saturated sodium chloride solution. The aqueous phases are extracted twice with 250 ml of diethyl ether each time. The organic phases are dried over sodium sulphate, concentrated by evaporation, and dissolved hot in 150 ml of cyclohexane. On cooling, 1 , 2 : 5, 6-di-O-isopropylidene-D- glucofuranose crystallises. The mother liquor is concentrated by evaporation, the residue is taken up in 120 ml of tetrahydrofuran, 24 ml of water and 4.5 ml of acetic acid, and the mixture is stirred at room temperature for 2 hours. Concentration by evaporation at room temperature under a high vacuum yields 10.6 g of residue, contamining (2R,3S)-2-amino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester. A sample (5 mg) is derivatlsed for 2 hours with 0.2 ml of trifluoroacetic acid anhydride in 0.3 ml of dichloromethane. Capillary gas chromatography (Chirasil®-L-Val , 90-180°/2° per minute) yields 99.25 % (2R,3S)-enantiomer (retention time Tret " 10.28 minutes) and 0.75 % (2S,3R)-enantiomer (retention time T _ β 11.48 minutes). The main mixture is then heated under reflux for ret 5 hours in 80 ml of formic acid ethyl ester. Concentration by evaporation and chromatography on silica gel using hexane/ethyl acetate 1:1 yield 1.64 g of formamide _1. Analysis of a sample (5 mg) in the form of the acetate by gas chromatography (Chirasil®-L-Val, 160-180°, 1° per minute): 99.2 % (2R, 3S)-enantiomer (T ■ 13.64 minutes), 0.8 % (2S,3R)-enantiomer (T = 13.94 minutes). a,b) Starting from isocyanoacetic acid ethyl ester 1.65 g of (S)-N-methyl-N-[2-(dimethylamino)-ethyl]-l-[(R)-l' ,2-bis-(di-phenylphosphino)-ferrocenyl)-ethylamine and 1.105 g of bis(cyclohexyl-isocyanide)gold(I) tetrafluoroborate are added at 50° to a solution of 24.88 g of isocyanoacetic acid ethyl ester and 18.51 g of methacrolein in 220 ml of 1 ,2-dichloromethane. The mixture is stirred at 50° for 5 hours under argon, concentrated by evaporation, taken up in 400 ml of diethyl ether and filtered, and the filtrate is concentrated by evaporation.
Distillation of the residue under a high vacuum (0.04 mbar) yields 33.62 g of a stereoisomeric mixture of 5-(2-propenyl)~oxazoline-4-carboxylic acid ethyl ester having a boiling point of 42-52°; MS.: m/e ■ 183 (2 %, M +), 110 (80 %), 85 (100 %) . A solution of 33 g of this mixture in 74 ml of water and 33 ml of tetrahydrofuran is heated under reflux for 3 hours. Concentration by evaporation in vacuo yields 36.1 g of a mixture of stereoisomeric 2-formamino-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester 2. A sample (35 mg) is derivatised in 2 ml of dichloromethane with 0.05 ml of Ν,Ο-bis-trimethylsilylacetamide and analysed by means of capillary gas chromatography (Chirasil®-L-Val, 150°): 89.1 % (2R,3S)-isomer (T - 22.1 minutes), 5.8 % (2S, 3R)-isomer (T . = 23.1 minutes), 2.8 % ( 2R, 3R)-isomer (T » 24.3 minutes), 2.3 % (2S,3S)-isomer (T B 25.4 minutes), ret A solution of 11.42 ml of acetic anhydride in 50 ml of dichloromethane is added dropwise at 0-3° within a period of 25 minutes to a solution of 20.2 g of 2, 16.83 ml of triethylamine and 0.62 g of 4-(dimethylamino)-pyridine in 300 ml of dichloromethane. After 30 minutes, the mixture is washed twice with ice-cold 2N hydrochloric acid and twice with 10 % sodium chloride solution. The aqueous phases are extracted with 100 ml of dichloromethane. The organic phases are dried over sodium sulphate and concentrated by evaporation, and the residue is dissolved hot in hexane/ ethyl acetate 4:1. On cooling slowly to approximately 30° there crystallise 1.82 g of racemic (2R*, 2S*)-2-formamino-3-acetoxy-4-methyl-4-pentenoic acid ethyl ester having a melting point of 98-106°. The mother liqour is slowly cooled to -12°C and kept at that temperature for one hour. Filtration yields 15.04 g of acetate 3, m.p. 73-75°, [α]ρ β -75.6° (c=l, CHC13), analysis by gas chromatography (Chirasil®-L-Val, 160-180°, 1° per minute): (2R,3S)-isomer 93.5 % (T = 14.5 minutes), (2S,3R)-isomer 2.2 % (T = 14.8 minutes), ( 2R, 3R)-isomer 2.2 % (T ret ret 16.8 minutes), (2S,3S)-isomer 2.1 % (T ■ = 17.1 minutes). ret 20.64 g of anhydrous potassium carbonate are added at -16° to a solution of (2R, 3S)-2-formylamino-3-acetoxy-4-methyl-4-pentenoic acid ethyl ester (3) in 400 ml of absolute ethanol. After stirring at -18° to -11°C for 4 hours, 500 ml of buffer solution (1 molar, phosphate, pH*7) are added dropwise. The mixture is stirred at room temperature for 30 minutes and extracted three times with 350 ml of dichloromethane each time. The organic phases are dried over sodium sulphate and concentrated by evaporation, and the residue is chromatographed on 1 kg of silica gel using hexane/ethyl acetate 1:2 as eluant, yielding 9.8 g of alcohol b) ( 2R)-2-formylamino-4-methyl-5-diisopropylphasphono-3-pentenoic acid ethyl ester (4) To a solution of 14.19 g of 1 according to a) in 210 ml of 1 , 2-dichloro-ethane there are added at 18-20° 6.57 ml of thionyl bromide and, after stirring for 2 hours, 135 ml of water. After 15 minutes, the organic phase is separated off and washed three times with 150 ml of ice-water each time and once with 100 ml of ice-cooled saturated sodium hydrogen carbonate solution. The organic phase is dried over sodium sulphate and concentrated by evaporation, and the residue is dissolved in 60 ml of triisopropyl phosphite and stirred at 75°/100 mbar for 17 hours. The excess reagent is distilled off at 90° under a high vacuum. Chromatography of the residue on 650 g of silica gel using ethyl acetate/methanol 20:1 yields 10.88 g of phosphonic acid ester 4, [α]Ώ * -123.5° (c»l, CHC13). XH- MR analysis (300 MHz) with the addition of (lR)-l-(9'-anthra-cenyl)-2,2,2-trifluoroethanol shows an enantiomeric purity of > 90 %. c) ( 2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester (5) 23 ml of trimethylbromosilane are added dropwise at room temperature within a period of 15 minutes to a solution of 10.3 g of 4 according to b) in 42 ml of dichloromethane. After 21 hours, 42 ml of ethanol are added while cooling with ice, and the mixture is stirred for 20 hours. The whole is then concentrated by evaporation and the residue is dissolved three times in 70 ml of toluene each time and in each case is concentrated by evaporation again. The residue is dissolved in 42 ml of ethanol, and 42 ml of propylene oxide are added. After 1 hours, the mixture is filtered. Drying the filtration residue in a vacuum desiccator over P205/KOH (3 hours/80o) yields 6.17 g of 5; [ct}D = -78° (c=0.6, H20) ; m.p. 194-197° (decomp.), C8Hi6N05P; calculated: C 40.51 %, H 6.80 %, N 5.91 %, P 13.06 %; found: C 39.4 %, H 7.09 %, N 5.73 %, P 12.98 .
In order to analyse the purity of the enantiomer, a sample is derivatised to the amide dimethyl phosphonate with (R)-(+)-methoxytrifluoromethyl-phenylacetic acid chloride and diazomethane and analysed by 1H-NMR (300 MHz) using the integration of the 0CH3 signals: (2R)-isomer ≥ 93 % (3.51 ppm) , (2S)-isomer ≤ 7 % (3.37 ppm).
Example 9 : (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid A solution of 100 mg of ( 2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester according to Example 5 in 3 ml of IN hydrochloric acid is heated in a bath at 100°C for 4 hours. The solution is concentrated by evaporation and the residue is dried at 60° under a high vacuum for 30 minutes. The residue is dissolved in 15 ml of ethanol, and 4 ml of propylene oxide are added thereto. Filtration and drying of the filtration residue in a vacuum desiccator over PaOs/KOH yield 62 mg of acid.
In order to determine the purity of the enantiomer, a sample is derivatised to the amide with (R)-(+)-methoxytrifluoromethylphenyl acetic acid chloride and is analysed by IH-NMR (300 MHz), integration of the OCH3 signals: > 95 % (2R)-enantiomer (3.25 ppm) and 5 % (2S)-enantiomer (3.18 ppm) .
Example 10: E-2-amino-4-methyl-5-phosphono-3-pentenoic acid 12 g of E-2-amino- -methyl-5-phosphono-3-pentenoic acid ethyl ester are stirred under reflux in 70 ml of water for 19 hours. The reaction mixture is slowly cooled to room temperature, stirred in an ice bath for one hour, filtered and washed with cold water. In this manner there is obtained E-2-amino-4-methyl-5-phosphono-3-pentenoic acid in the form of the monohydrate, m.p. 163° (decomp.).
Example 11 : E-2-dimethylamino-4-methyl-5-phosphono-3-pentenoic acid A mixture of 3.56 g of E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester, 45 ml of 98 % formic acid and 30 ml of 37 % aqueous formaldehyde solution is stirred at a bath temperature of 105° for 30 minutes. The mixture is then concentrated to dryness by evaporation in vacuo. The residue is taken up in a little water and the whole is again concentrated by evaporation in vacuo. This procedure is repeated twice more. The solid residue is stirred with 80 ml of water. After one hour, the undissolved material is separated off over a hard filter and washed with water. The filtrate and the washing water are concentrated to dryness by evaporation in vacuo. The residue is suspended in 100 ml of water and, after the addition of 30 ml of IN sodium hydroxide solution, is left to stand at room temperature for 2 days. The reaction mixture is concentrated to a residual volume of approximately 25 ml by evaporation in vacuo and purified by ion exchanger chromatography (Dowex 50 W x 8 H_0) . The fractions which contain the desired product are combined, concentrated by evaporation in vacuo and recrystallised from water/ ethanol. In this manner there is obtained E-2-dimethylamino-4-methyl-5-phosphono-3-pentenoic acid, m.p. 239° (decomp.).
Example 12 : E-2-dimethylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester 30 ml of 8N ethanolic hydrogen chloride solution are added to 1.19 g of E-2-dimethylamino-4-methyl-5-phosphono-3- pentenoic acid, and the mixture is stirred at 40° for 24 hours. The reaction mixture is concentrated to dryness by evaporation in vacuo. After the addition of 30 ml of pure ethanol, the mixture is again concentrated by evaporation, giving 1.90 g of reddish oil, which is dissolved in hot isopropanol. After cooling there is obtained crystalline E-2-dimethylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester hydrochloride, m.p. 203° (decomp.).
Example 13: E-2-benzylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester 16 ml of glacial acetic acid, 5.90 g of sodium acetate (anhydrous) and 12.2 ml of benzaldehyde are added to a solution of 5.69 g of E-2-amino-4-methyl-5-phosphono-3- pentenoic acid ethyl ester in 48 ml of water and 48 ml of ethanol. 15.70 g of sodium borohydride are added in approximately 70 portions within a period of one hour with intensive cooling with ice/ sodium chloride, 4 ml of benzaldehyde being added after half the addition has taken place, after approximately 30 minutes. The temperature of the reaction mixture is kept at from 0 to 10°. When the addition is complete, the mixture is stirred at 0° for one hour to complete the reaction, and then IN hydrochloric acid is added dropwise until an acidic reaction to Congo red takes place. The undissolved salts are filtered off and washed with water. The filtrate is concentrated to dryness by evaporation in vacuo, and the residue is concentrated by evaporation twice more after the addition of ethanol. The residue is then stirred with 150 ml of ethanol, and the undissolved material is filtered off with suction and washed with ethanol. 25 ml of propylene oxide are added to the filtrate, and the mixture is then stirred for 2 hours. The material which crystallises out (mainly educt) is filtered off. The mother liquor is concentrated to dryness by evaporation and stirred with 350 ml of ethyl acetate. The crystalline crude product obtained after filtration with suction is recrystallised from ethanol. In this manner there is obtained E-2-benzylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester, m.p. 192° (deco p.).
Example 14 : E-2-benzylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester A solution of 1.00 g of E-2-benzylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester in 6 ml of water is stirred under reflux for 20 hours. The reaction mixture is concentrated to dryness by evaporation in vacuo. Ethanol is added to the residue, and the mixture is again concentrated by evaporation. This process is repeated twice more. The residue is dissolved in boiling methanol. After cooling there is obtained crystalline E-2-benzylamino-4-methyl-5-phosphono-3-pentenoic acid, m.p. 150° (decomp.).
Example 15: E-2-isopropylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester 6.64 g of sodium acetate (anhydrous) and 18 ml of acetone are added to a solution of 6.40 g of E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester in 54 ml of water and 18 ml of glacial acetic acid. 17.67 g of sodium borohydride are added in approximately 70 portions within a period of 90 minutes with intensive cooling with ice/sodium chloride, 18 ml of acetone being added after 20 minutes and after 50 minutes. When the addition is complete, the thick white suspension is stirred at 0° for 30 minutes to complete the reaction, and then IN hydrochloric acid is added dropwise until an acidic reaction to Congo red takes place. The resulting clear solution is concentrated by evaporation in vacuo, and the residue is concentrated by evaporation twice more after the addition of ethanol. The residue is then stirred with 200 ml of ethanol at room temperature, and the undissolved material is filtered off and washed with ethanol. The filtrate is concentrated by evaporation in vacuo, and the residue is recrystallised from isopropanol. In this manner there is obtained E-2-isopropylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester hydrochloride, m.p. 203-205° (decomp.).
Example 16: E-2-isopropylamino-4-methyl-5-phosphono-3-pentenoic acid A solution of 1.20 g of E-2-isopropylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester hydrochloride in 7 ml of water is stirred under reflux for 20 hours. The reaction mixture is concentrated to dryness by evaporation in vacuo. Ethanol is added to the residue, and the mixture is again concentrated by evaporation. This process is repeated twice more. The residue is dissolved in 25 ml of ethanol, a total of 5 ml of propylene oxide is added dropwise thereto with stirring, and the whole is concentrated to dryness by evaporation. The residue is dissolved in a little water, and ethanol is added until the solution becomes cloudy. The solution is stirred at room temperature for 4 hours to complete the reaction, during which time crystallisation slowly takes place. The product is filtered off, washed with ethanol and diethyl ether and dried at 100° under a high vacuum. In this manner there is obtained E-2-iso-propylamino-4-methyl-5-phosphono-3-pentenoic acid, m.p. 225-227° (decomp. ) .
Example 17 : E-2-methylamino-4-methyl-5-phosphono-3-pentenoic acid a) 2-(N-methyl-N-formylamino)-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester O) 20.60 g of 5-(2-propenyl)-2-oxazoline-4-carboxylic acid ethyl ester, prepared according to Example 1, are dissolved in 200 ml of dry dichloromethane under argon. A suspension of 16.60 g of trimethyloxonium tetra-fluoroborate in 200 ml of dry dichloromethane is then added dropwise at 15°. The reaction mixture is stirred at room temperature for 17 hours, and then 150 ml of water and 45 ml of saturated potassium bicarbonate solution are added slowly, so that a pH of 7 is produced. The organic phase is separated off and washed twice with water and once with saturated sodium chloride solution, and is then dried over sodium sulphate. After the dichloromethane has been distilled off, the oily residue is distilled in a bulb tube, b.p. 120-130°/13 Pa. In this manner there is obtained 2-(N-methylformylamino)-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester in the form of a light-yellow honey, IR (CH2C12): 3550 (HO); 1740 (CO ester); 1675 (CO amide). b) E-2-(N-methyl-N-formylamino)-4-methyl-5-diisopropyl-phosphono-3- pentenoic acid ethyl ester (2) 7.70 ml of thionyl bromide are added dropwise at 20° under argon to a solution of 17.80 g of 2-(N-methylformylamino)-3-hydroxy-4-methyl-4-pentenoic acid ethyl ester in 248 ml of 1 ,2-dichloroethane. The mixture is stirred at room temperature for 2 hours. 150 ml of water are then added dropwise with slight cooling (20°). The two-phase mixture is stirred thoroughly for a further 20 minutes to complete the reaction. The organic phase is separated off and washed three times with water/ice, once with ice/saturated potassium bicarbonate solution and once with saturated sodium chloride solution. To the intermediate obtained after drying over sodium sulphate and removal of the 1 , 2-dichloroethane by distillation at 35° in vacuo there are added at room temperature 66 ml of triisopropyl phosphite, and the mixture is then stirred at 75° under reduced pressure (approximately 13 kPa) for 17 hours. The excess triisopropyl phosphite and other volatile by-products are then distilled off under a high vacuum. Purification by column chromatography (silica gel, ethyl acetate) yields E-2-(N-methylformylamino)-4-methyl-5-diisopropyl-phosphono-3-pentenoic acid ethyl ester in the form of a yellowish honey; IR (CH2Clz): 1740 (CO ester); 1670 (CO amide); 1235 (P-0); 980-1010 (P-0-C). According to the IH-NMR spectrum, the compound is in the form of a mixture of two rota ers. c) E-2-methylamino-4-methyl-5-phosphono-3-pentenoic acid (3) 20 ml of trimethylbromosilane are added dropwise at 20° within a period of 10 minutes under argon to a solution of 9.50 g of E-2-(N-methylformyl-amino)-4-methyl-5-diisopropylphosphono-3-pentenoic acid ethyl ester in 40 ml of dry dichloromethane. After stirring at room temperature for 20 hours, 37 ml of ethanol are added dropwise within a period of 15 minutes, and the whole is stirred for a further 20 hours. The clear reaction solution is then concentrated to dryness by evaporation in vacuo. The residue is concentrated by evaporation twice more in each case after the addition of 30 ml of toluene. 128 ml of 2N hydrochloric acid are added to the resulting oil, and the mixture is stirred at a bath temperature of 85° for 16 hours. The reaction mixture is concentrated by evaporation in vacuo. Concentration by evaporation twice after the addition of ethanol/toluene 1:1 yields an oily residue, which is dissolved in 51 ml of ethanol and to which there is added dropwise a solution of 51 ml of propylene oxide in 51 ml of ethanol. The product obtained in crystalline form is filtered off after 2 hours and re-crystallised from water/ethanol. In this manner there is obtained E-2-methylamino-4-methyl-5-phosphono-3-pentenoic acid, m.p. 239° (decomp.).
Example 18 : The following can also be prepared in a manner analogous to that described in Examples 1-3 or 5 and 8: E--2--amino-5-phosphino-3-pentenoic acid ethyl ester, m.p. 172-173°; E-•2· -amino-5-phosphino-3-pentenoic acid butyl ester, m.p. 160-161°; E--2--amino-5-phosphono-3-pentenoic acid ethyl ester, m.p. 167-168°; E-■2--amino-5-phosphono-3-pentenoic acid butyl ester, m.p. 160-161°; E--2· -amino-5-phosphono-3-pentenoic acid octyl ester, m.p. 161-162°; E-•2· -amino- -phosphono-3-pentenoic acid propyl ester, m.p. 161-162°; E-■2· -amino-5-phosphono-3-pentenoic acid pentyl ester, m.p. 160-161°; E--2· -amino-5-phosphono-3-pentenoic acid isobutyl ester, m.p. 163-164°; E-■2· -amino-5-phosphono-3-pentenoic acid sec. -butyl ester, m.p. 169-170°; E-■2--amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester, m. P . 193-194°, [water/acetone (9:1)]; E-■2· -amino-4-methyl-5-phosphono-3-pentenoic acid n-propyl ester, m. P . 184-185°, (water); E-2-amino-4-methyl-5-phosphono-3-pentenoic acid n-butyl ester, m.p. 186-187°, [water/acetone (2:1)]; E-2-amino-4-methyl-5-phosphono-3-pentenoic acid isobutyl ester, m.p. 181-182°, [water/acetone (9:1)]; E-2-amino-4-inethyl-5-phosphono-3-pentenoic acid n-pentyl ester, m.p. 207-208°; E-2-amino-4-methyl-5-phosphono-3-pentenoic acid n-hexyl ester, m.p. 207-208°; E-2-aroino-7-phosphono-4-heptenoic acid butyl ester, m.p. 186°; E-2-amino-5-phosphonc—4-pentenoic acid methyl ester, m.p. 219-220°; E-2-amino-5-phosphono-4-pentenoic acid ethyl ester, m.p. 234°; E-2-amino-5-phosphono-4-pentenoic acid butyl ester, m.p. 239°; E-2-amino-5-phosphono-4-pentenoic acid octyl ester, m.p. 236°; E-2-amino-5-phosphono-4-pentenoic acid 2-hydroxyethylester , m.p. 197°.
Example 19: The following can also be prepared in a manner analogous to that described in Examples 10, 11, 16 and 17 or 4, 6, 7, 8 and 9: E-2-amino-5-phosphono-4-pentenoic acid, m.p. 219-220°; E-2-amino-5-methylphosphonyl-4-pentenoic acid, m.p. 222°; E-2-amino-5-butylphosphonyl-4-pentenoic acid, m.p. 232-233°; E-2-amino-5-octylphosphonyl-4-pentenoic acid, m.p. 221-223°; E-2-amino-5-dodecylphosphonyl-4-pentenoic acid, m.p. 211°; E-2-amino-6-phosphono-4-hexenoic acid, m.p. 244-246°; E-2-amino-6-methylphosphonyl-4-hexenoic acid, m.p. 145-150°; E-2-amino-6-butylphosphonyl-4-hexenoic acid, m.p. 216°; E-2-amino-6-octylphosphonyl-4-hexenoic acid, m.p. 209-210°; E-2-amino-6-dodecylphosphonyl-4-hexenoic acid, m.p. 197-200°; E-2-amino-7-phosphono-4-heptenoic acid, m.p. 125° (decomposition); (2R)-E-2-amino-4-fluoro-5-phosphono-3-pentenoic acid, [<*]ρ = -44.8° (c=0.5; H20); 13 C-NMR-spectrum (75 MHz, D20): 172.7 (COOH); 161.5 (dxd, j=263+12: C ; 100.9 (t, J-ll: C3); 49.5 (C2) 33.5 (dxd, J=128+26: C5); E-2-amino-5-phosphono-3-pentenoic acid, white amorphous powder, 1H-NMR (D20): 2.39 (dd, 2H, C(5)-H); 4.27 (d, 1H, C(2)-H); 5.53 (m, 1H, C(3)-H); 5.87 (m, 1H, C(4)-H); m.p. after recrystallisation from ethanol/water 191-192°; E-2-amino-4-methyl-5-phosphono-3-pentenoic acid, 1H-NMR (D20) : 1.73 (s, 3H, CH3); 4.55 (s, 1H, C(2)-H); E-2-amino-5-methylphosphonyl-3-pentenoic acid, amorphous white powder, 1 H-NMR (D20): 2.55 (dd, 2H, C(5)-H) 4.38 (d, 1H, C(2)-H); 5.64 (m, 1H, C(3)-H); 5.91 (m, 1H, C(4)-H); E-2-amino-5-phosphino-3-pentenoic acid, m.p. 139-140°; E-2-amino-4-methyl-5-phosphino-3-pentenoic acid, m.p. 176-177°; (2S)-E-2-amino-4-methyl-5-phosphono-3-pentenoic acid, m.p. 196°, [a] « +97.1 ± 1.9° Example 20: E-2-methylamino-4-inethyl-3-pentenoic acid ethyl ester 50 ml of 8N ethanolic hydrogen chloride solution are added to 1.20 g of E-2-methylamino-4-methyl-5—phosphono-3-pentenoic acid, and the mixture is stirred at 40° for 25 hours. The reaction mixture is concentrated to dryness by evaporation in vacuo. Concentration by evaporation twice after the addition of ethanol/ toluene 1:1 yields an oily residue, which is dissolved in 5 ml of ethanol and to which there is added dropwise a solution of 5 ml of propylene oxide in 5 ml of ethanol. The product obtained in crystalline form is filtered off after 2 hours and washed with ethanol and ether. After drying (80°, 4 hours) under a high vacuum, there is obtained E-2-methylamino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester, m.p. 235-240° (with decomposition).
Example 21: Preparation of 1000 capsules each containing 10 mg of the active ingredient of Example 6 and having the following composition: E-2-amino-6-phosphono-4-hexenoic acid 10.0 g lactose 207.0 g modified starch 80.0 g magnesium stearate 3.0 g Method: All the pulverulent constituents are sieved through a sieve having a mesh width of 0.6 mm. The active ingredient is then placed in a suitable mixer and mixed first with the magnesium stearate and then with the lactose and starch, until a homogeneous mixture is obtained. No. 2 gelatin capsules are each filled with 300 mg of this mixture, a capsule-filling machine being used.
Capsules that contain from 10 to 200 mg of one of the other disclosed compounds mentioned in Examples 1-19 are prepared in analogous manner.
Example 22: Preparation of 10,000 tablets each containing 10 mg of the active ingredient of Example 6 and having the following composition: E-2-amino-6-phosphono-4-hexenoic acid 100.00 g lactose 2535.00 g corn starch 125.00 g polyethylene glycol 6000 150.00 g magnesium stearate 40.00 g purified water q. s .
Method: All the pulverulent constituents are sieved through a sieve having a mesh width of 0.6 mm. The active ingredient is then mixed in a suitable mixer with the lactose, the magnesium stearate and half of the starch. The other half of the starch is suspended in 65 ml of water, and the suspension is added to a boiling solution of the polyethylene glycol in 260 ml of water. The resulting paste is added to the powders and the mixture is granulated, if necessary with the addition of more water. The granulate is dried overnight at 35°, forced through a sieve having a mesh width of 1.2 mm, and compressed to form tablets which have a breaking groove .
Tablets that contain from 10 to 200 mg of one of the other disclosed compounds mentioned in Examples 1-19 are prepared in analogous manner.
Claims (1)
1. 87246/4 - 62 - Patent Claims 1. A process for the manufacture of unsaturated amino acid compounds of formula in which i is hydrogen, alkyl or hydroxy, ¾ is hydrogen, alkyl, halo- alkyl, hydroxyalkyl, lower alkoxyalkyl, phenyl-lower alkyl or phenyl- lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkenyl, halogen, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, 3 is hydrogen, alkyl, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy ,. halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, Ri, is hydrogen or alkyl, R5 is carboxy, lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycarbonyl, lower alkanoyloxy-substituted methoxycarbonyl, lower alkoxymethoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[2.2.1 Jhept-yloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl or N-(di-lower alkylamino) -lower alkylcarbamoyl, Re is an amino group that is unsubstituted or substituted by alkyl or by phenyl-lower alkyl or phenyl-lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, A is unsubstituted or alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms (C-atoms) or is a direct bond, and B is methylene or a bond, with the proviso that A is unsubsti- tuted or alkyl-substituted cc , ω-alkylene having from 1 to 3 C-atoms when B is a direct bond, and to the salts thereof, characterised in that in a compound of formula in which z1 is free or protected hydroxy, Z2 is an Rx group or protected hydroxy, Z6 an Rs group or protected carboxy, Zs is a protected group R6, and Ri , R2, R3, R4, Rs, R6, A and B are as defined above, the protected groups Z6 and, when applicable, Zi, ∑ 2 and/or Zs are freed by treatment with a tri-lower alkylhalo- silane and, if desired, the resulting compound is converted into a different compound of formula I, a resulting mixture of optical isomers is resolved into the components and the desired isomer is separated off, and/or a resulting free compound is converted into a salt or a resulting salt is converted into the free compound or into a different salt. /JUL/88 2. A process according to claim 1, characterised in that a compound of formula in which 2 , R3 , Ri» , A and B are as defined for formula I, Z5 has the meaning of R5 or is protected carboxy, Z is a protected group Re, and X is reactive esterified hydroxy, is reacted with a compound of formula in which Zi is free or Z2 has the meaning of R\ or is and R is an etherifying group, in the resulting intermediate of formula (II), - 64 - the protected groups Zs and, when applicable, Zi , Zz and/or Z5 are freed by treatment with a tri-lower alkylhalosilane and, if desired, in a compound obtainable according to the process in which R5 is esterified carboxy, the esterified carboxy group is converted into carboxy or, in a /JUL/88 compound obtainable according to the process in which R5 is carboxy, the carboxy group is converted into an esterified carboxy group and/or, if desired, a resulting compound of formula I is converted into a salt or a resulting salt is converted into a different salt or into a free compound of formula I and/or, if desired, an optical isomer is isolated from a mixture of stereoisomeric forms of a resulting compound of formula I or of a salt thereof. 3. A process according to claim 1 for the manufacture of compounds of formula I in which Ri , R2 , R3, R, , A and B are as defined in claim 1, R5 is lower alkoxycarbonyl , phenyl-lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycarbonyl , lower alkanoyloxy-substituted methoxycarbonyl , lower alkoxymethoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[ 2.2.1 jheptyloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkyl- carbamoyl, di-lower alkylcarbamoyl or N-(di-lower alkylamino)-lower alkylcarbamoyl , and R6 denotes amino or mono-lower or di-lower alkylamino and salts thereof, characterised in that a compound of formula in which R2 , R3 , , A and B are as defined for formula I, Z 5 has the meaning of R5 , Z& is protected amino, and X is reactive esterified hydroxy, is reacted with a compound of formula - 65 - in which Z is free or Z∑ has the meaning of Ri or is and R is an etherifying group, in the resulting intermediate the protected groups Z$ and, when applicable, Zi and/or Z 2 are freed, whilst R5 is retained, by treatment with trimethylbromosilane and, if desired, a resulting compound of formula I is converted into a salt or a resulting salt is converted into a different salt or into a free compound of formula I and/or, if desired, an optical isomer is isolated from a mixture of stereoisomeric forms of a resulting compound of formula I or of a salt thereof. 4. A process according to claim 1 for the manufacture of compounds of formula I in which Ri , R∑ , R3 , Ri, , R6 , A and B are as defined in claim 1 and R5 is carboxy, and the salts thereof, characterised in that in a compound of formula II in which Z\ is free or 2 is an Ri group or Z5 is free or protected carboxy and ∑ is protected group Re and Ri , R2 , R3 , Ri, , R , A and B are as defined above, the protected groups Ζβ and, when applicable Zi, Z2 and/or Z5 are freed by treatment with a tri-lower alkylhalosilane and, if desired, in a compound obtainable according to the process in which Rs is esterified carboxy, the esterified carboxy group is converted into carboxy or, in a compound obtainable according to /JUL/88 the process in which R5 is carboxy, the carboxy group is converted into an esterified carboxy group and/or, if desired, a resulting compound of formula I is converted into a salt or a resulting salt is converted into a different salt or into a free compound of formula I and/or, if desired, an optical isomer is isolated from a mixture of stereoisomeric forms of a resulting compound of formula I or of a salt thereof. 5. A process according to any one of claims 1, 2 and 4, characterised in that the starting material used is a compound of formulae II or IV in which ∑i and/or Z2 is hydroxy etherified by an aliphatic alcohol, such as hydroxy etherified by a lower alkanol, lower alkenol or lower alkynol each of which is unsubstituted or substituted by halogen or, in a position higher than the o-position, by hydroxy, oxo, lower alkoxy, lower alkanoyloxy and/or by mono- or di-lower alkylamino. - 66 - 6. A process according to claim 3, characterised in that the starting material used is a compound of formula IV in which Zi and/or Zz is hydroxy etherified by an aliphatic alcohol, such as hydroxy etherified by a lower alkanol, lower alkenol or lower alkynol each of which is unsubsti- tuted or substituted by halogen or, in a position higher than the /JUL/88 ct-position, by hydroxy, oxo, lower alkoxy, lower alkanoyloxy and/or by mono- or di-lower alkylamino. 7. A process according to any one of claims 1, 2 and h, characterised in that the starting material used is a compound of formulae II or IV in which i and/or Z2 is lower alkoxy. 8. A process according to claim 3, characterised in that the starting material used is a compound of formula IV in which Z\ and/or 2 is lower alkoxy . 9. A process according to any one of claims 1 to 8, characterised in that the starting material used is a compound of formulae II or III in which /JUL/88 the protected group Ζβ is an acylamino group, optionally N-substituted by lower alkyl or phenyl-lower alkyl. ess according to any one of claims 3, 6 and 8, characterised in tarting material used is a compound of formula III in which the group Z6 is an acylamino group. 11. A process according to any one of claims 1 to 9, characterised in that the starting material used is a compound of formulae II or III in which the protected group Ζε is the acyl group of a carbonic acid semi- ester. /JUL/88 12. A process according to any one of claims 1 to 9, characterised in that the starting material used is a compound of formulae II or III in which the protected group Z is a lower alkoxycarbonylamino group that is unsubstituted or substituted in the 1- or 2-position, for example tert.- bu oxycarbonylamino . - 67 13. A process according to any one of claims 1 to 8, characterised in that the starting material used is a compound of formulae II or III in /JUL/88 which the protected group ε is a lower alkanoylamino group, optionally N-substituted by lower alkyl or phenyl-lower alkyl, for example formyl- amino . 14. A process according to any one of claims 3, 6, 8 and 10, characterised in that the starting material used is a compound of formula III in which the protected group Z is a lower alkanoylamino group, for example formylamino . 15. A process according to any one of claims 1 to 14, characterised in that the tri-lower alkylhalosilane used is a tri-lower alkylchlorosilane , tri-lower alkyliodosilane or tri-lower alkylbromosilane . /JUL/88 16. A process according to any one of claims 1 to 1A, characterised in that the tri-lower alkylhalosilane used is a tri-lower alkylbromosilane. 17. A process according to any one of claims 1, 2, 4, 5, 7, 9, 11 to 13, 15 and 16, characterised in that the tri-lower alkylhalosilane used is trimethylbromosilane . 18. A process according to any one of claims 3, 6, 10 and 14, characterised in that the tri-lower alkylhalosilane used is trimethylbromosilane . 19. A process according to any one of claims 1, 2, 4, 5, 7, 9, 11-13 and /JUL/88 I 15 to 17, characterised in that the protected groups Zi , Zz , Zs and/or Z& are freed in a halogenated hydrocarbon. 20. A process according to any one of claims 3, 6, 8, 10, 14 and 18, characterised in that the protected groups Ζχ, Z∑ , Z5 and/or Ζβ are freed in a halogenated hydrocarbon. 21. A process according to any one of claims 1 to 20, characterised in /JUL/88 that the protected groups Z\ , Z2, Z5 and/or Z¾ are freed in a halogenated aliphatic hydrocarbon. - 68 - 22. A process according to any one of claims 1, 2, 4, 5, 7, 9, 11-13, I28/JUL/88 15 to 17 and 19, characterised in that the reaction is carried out in dichloromethane as solvent or diluent. 23. A process according to any one of claims 3, 6, 8, 10, 14, 18 and 20, characterised in that the reaction is carried out in dichloromethane as solvent or diluent. 24. A process according to any one of claims 1 to 23, characterised in 28/JUL/88 that a substance absorbing hydrogen halide is added. 25. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20 and 23 characterised in that a substance absorbing hydrogen bromide added. 26. A process according to any one of claims 1 to 25, characterised in that an epoxy-lower alkane in admixture with a lower alkanol is added as substance absorbing hydrogen halide. 28/JUL/88 27. A process according to any one of claims 1, 2, 4, 5, 7, 9, 11-13, 15-17, 19, 21, 22 and 24, characterised in that propylene oxide in admixture with ethanol is added as substance absorbing hydrogen halide. 28. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23 and 25, characterised in that propylene oxide in admixture with ethanol is added as substance absorbing hydrogen bromide. ms 1 to 28 for the manufacture mula Rz is hydrogen, alkyl, halo- enyl-lower alkyl or phenyl- droxy, lower alkoxy, halogen, 87246/3 - 69 - amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkenyl, halogen, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, R3 is hydrogen, alkyl or phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or^by nitro, R is hydrogen or alkyl, R5 is carboxy, lower alkoxycar-bonyl, phenyl-lower alkoxycarbonyl , phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycar-bonyl, lower alkanoyloxy-substituted methoxycarbonyl, lower alkoxy-methoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[2.2.1 Jheptyloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkylcar-bamoyl, di-lower alkylcarbamoyl or N-(di-lower alkylamino) -lower alkyl-carbamoyl, R6 is an amino group that is unsubstituted or substituted by alkyl or by phenyl-lower alkyl or phenyl-lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, A is unsubstituted or alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms (C-atoms) or is a direct bond, and B is methylene or a bond, with the proviso that A is unsubstituted or alkyl-substituted α,ω-alkylene having from 1 to 3 C-atoms when B is a direct bond, in the form of those enantiomers in which the C-atom carrying the amino group R$ is in the R-configuration, and the salts thereof, characterised in that the starting material used is a compound of formula IV or compounds of formulae II and III in which the C-atom carrying the Ζε group is in the R-configuration. 30. A process for the manufacture of unsaturated amino acid compounds formula (la) 87246/3 - 70 - in which Ri is hydrogen, alkyl or hydroxy, R2 is hydrogen, alkyl, halo- alkyl, hydroxyalkyl, lower alkoxyalkyl, phenyl-lower alkyl or phenyl- lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkenyl, halogen or aryl, R3 is hydrogen, alkyl, phenyl or phenyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, Ri, is hydrogen or alkyl, R5 is carboxy, Re is an amino group that is unsubstituted or substituted by alkyl or by phenyl-lower alkyl or phenyl-lower alkyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, A is unsubstituted or alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms (C-atoms) or is a direct bond, and B is methylene or a bond, with the proviso that A is unsubstituted or alkyl- substituted α,ω-alkylene having from 1 to 3 C-atoms when B is a direct bond, and the salts thereof, characterised in that a compound of formula in which R5 is an esterified carboxy group, is hydrolysed in water without the addition of acid or base. 31. A process according to claim 30, characterised in that the starting material used is a compound of formula lb in which R5 is a lower alkoxy- carbonyl group. 32. A process according to any one of claims 1 to 31 , characterised in that a compound of formula I in which Ri is hydrogen, alkyl having up t and including 12 carbon atoms, or hydroxy, ¾ is hydrogen, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, phenyl lower alkyl that is unsubstituted or substituted in the phenyl moiety a /JUL/88 indicated, lower alkenyl, halogen, phenyl or phenyl substituted as indicated, R3 is hydrogen, lower alkyl, phenyl or phenyl substituted as indicated, Ri» is hydrogen or lower alkyl, R5 is carboxy, lower alkoxy- carbonyl, phenyl-lower alkoxycarbonyl , phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo- lower alkyl, hydroxy-lower alkyl, araino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the ot-posit on by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycar- bonyl, lower alkanoyloxy-substituted methoxycarbonyl , lower alkoxy- methoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[2.2.1 Jheptyloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkylcar-/JUL/88 bamoyl, di-lower alkylcarbamoyl or N-(di-lower alkylamino)-lower alkyl- carbamoyl, R$ is amino, or mono- or di-lower alkylamino, A is unsubsti- tuted or lower alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms or is a bond, and B is methylene or a bond, with the proviso that A is other than a bond when B is a bond, the substituents of phenyl being selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl and nitro, or a pharmaceutically acceptable salt thereof, is manufactured. 33. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23, 25 and 28, characterised in that a compound of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, phenyl-lower alkyl that is unsubstituted or substituted in the phenyl moiety as indicated, lower alkenyl, halogen, phenyl or phenyl substituted as indicated, R3 is hydrogen, lower alkyl, phenyl or phenyl substituted as indicated, Ri, is hydrogen or lower alkyl, R5 is carboxy, lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl, phenyl-lower alkoxycarbonyl substituted by lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl or by nitro, lower alkoxy carbonyl substituted in a position higher than the a-position by amino, mono- or di-lower alkylamino or hydroxy, lower alkoxycarbonyl substituted by carboxy or by lower alkoxycarbonyl, pyridylmethoxycarbonyl, lower alkanoyloxy-substituted methoxycarbonyl, lower alkoxymethoxycarbonyl substituted by lower alkanoyloxy or by lower alkoxy, bicyclo[ 2.2.1 Jheptyloxycarbonyl-substituted methoxy carbonyl or lower alkoxycarboyloxy-lower alkoxy carbonyl or carbamoyl, lower alkylcarbamoyl, di-lower alkylcarbamoyl or N-(di-lower alk lamino)-lower alkylcarbamoyl , R6 is amino, or mono- or di-lower alkylamino, A is unsubstituted or lower alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms or is a bond, and B is methylene or a bond, with the proviso that A is other than a bond when B is a bond, the substituents of phenyl being selected from the group consisting of lower alkyl, hydroxy, lower alkoxy, halogen, amino, halo-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl and nitro, or a pharmaceutically acceptable salt thereof, is manufactured. 34. A process according to claim 33, characterised in that a compound of formula I in which Ri to Rt, , A and B are as defined in claim 33, Rs is lower alkoxycarbonyl or lower alkoxycarbonyl substituted by amino, niono- or di-lower alkylamino, hydroxy or by lower alkanoyloxy and R6 is amino or mono-lower alkylamino, or a pharmaceutically acceptable salt thereof, is manufactured. 35. A process according to any one of claims 1 to 31, characterised in that a compound of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl, phenyl, halophenyl or phenyl-lower alkyl, R3 and Ru are hydrogen or lower /JUL/88 alkyl R5 is carboxy and R6 is amino, A being unsubstituted or lower alkyl-substituted α,ω-alkylene having from 1 to 3 carbon atoms or being a bond and B in each case being methylene or a bond, with the proviso that A is other than a bond when B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 36. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23, 25 and 28, characterised in that a compound of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl, phenyl, halophenyl or phenyl-lower alkyl, R3 and Rt, are hydrogen or lower alkyl and, on the one hand, R5 is alkoxycarbonyl or hydroxy-lower alkoxycarbonyl and Re is amino or mono-lower alkylamino, A representing unsubstituted or lower alkyl-substituted α,ω- alkylene having from 1 to 3 carbon atoms or representing a bond and B representing methylene or a bond, with the proviso that A is other than a bond when B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. - 73 37. A process according to any one of claims 1 to 31, characterised in that a compound of formula I in which Ri is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R∑ is hydrogen, lower alkyl or halophenyl, R3 is hydrogen or halophenyl, Ri, is hydrogen, Rs is carboxy and R6 is amino, A being ot, w-alkylene having from 1 to 3 carbon atoms or being a bond and B in each case being methylene or a bond, with the proviso that A is other than a bond when B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 38. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23, 25 and 28, characterised in that a compound of formula I in which i is hydrogen, alkyl having up to and including 12 carbon atoms, or hydroxy, R2 is hydrogen, lower alkyl or halophenyl, R3 is hydrogen or halophenyl, Ri, is hydrogen, R5 is lower alkoxycarbonyl or hydroxy-lower alkoxy-carbonyl and R6 is amino or mono-lower alkylamino, with the proviso that A is other than a bond when B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 39. A process according to any one of claims 1 to 31, characterised in that a compound of formula I in which Ri is hydrogen, lower alkyl or hydroxy, R2 is hydrogen or lower alkyl, R3 and Ri, are hydrogen, Rs is lower alkoxycarbonyl and R6 is amino, A representing α,ω-alkylene having from 1 to 3 carbon atoms and B representing a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 40. A process according to any one of claims 3, 6^ 8, 10, 14, 18, 20, 23, 25 and 28, characterised in that a compound of formula I in which Ri is hydrogen, lower alkyl or hydroxy, R2 is hydrogen or lower alkyl, R3 and Ri« are hydrogen, Rs is lower alkoxycarbonyl and Rs is amino, A representing α,ω-alkylene having from 1 to 3 carbon atoms and B representing a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 87246/3 - 74 - 41. A process according to any one of claims 1, 2 and 4 to 31, characterised in that a compound of formula I in which Ri is hydroxy, R¾ is /JUL/88 hydrogen or lower alkyl, R3 and Ri, are hydrogen, R5 is lower alkoxy- carbonyl or carboxy, R6 is amino, A is methylene and B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 42. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23, 25, 28 and 31, characterised in that a compound of formula I in which Ri is hydroxy, R2 is hydrogen or lower alkyl, R3 and Ri, are hydrogen, R5 is lower alkoxycarbonyl or carboxy and R6 is amino, A is methylene and B is a bond, or a pharmaceutically acceptable salt thereof, is manufactured. 43. A process according to any one of claims 3, 6, 8, 10, 14, 18, 20, 23, 25 and 28, characterised in that E-2-amino-4-methyl-5-phosphono-3- penteno c acid ethyl ester or a pharmaceutically acceptable salt thereof is manufactured. 44. A process according to any one of claims 1, 2 and 4 to 28, charac- terised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid or a pharmaceutically acceptable salt thereof is manufactured. 45. A process according to claim 29, characterised in that E-2-amino- - methyl-5-phosphono-3-pentenoic acid or a pharmaceutically acceptable salt thereof is manufactured. /JUL/88 46. A process according to claim 1 for the manufacture of E-2-amino-5- phosphono-pentenoic acid and pharmaceutically acceptable salts thereof, characterised in that E-2-formylamino-4-diethylphosphonomethyl-3, 6-hepta- dienoic acid methyl ester is reacted with trimethyliodosilane in dichloromethane and the primary product is treated with hydrochloric acid . 47. A process according to any one of claims 1 to 46, characterised in that that enantiomer is produced in which the C-atom carrying the amino group e has the R-configuration . 87246/5 - 75 - 48. A process according to any one of claims 1 to 31, characterised in that (2R)-E-2-amino-4-methyl-5-phosphono-3-pentenoic acid or a pharmaceutically acceptable salt thereof is manufactured. 49. A process according to any one of claims 1 to 29, characterised in that (2R)-E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester or a pharmaceutically acceptable salt thereof is manufactured. 50. A process according to any one of claims 1 to 31, characterised in that ( 2R) -2-amino-4-methyl-7-phosphono-3-heptenoic acid or a pharmaceutically acceptable salt thereof is manufactured. 51. A process according to any one of claims 1 to 29, characterised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid methyl ester or a pharmaceutically acceptable salt thereof is manufactured. /JUL/88 52. A process according to any one of claims 1 to 29, characterised in that E-2-araino-4-methyl-5-phosphono-3-pentenoic acid n-propyl ester or pharmaceutically acceptable salt thereof is manufactured. 53. A process according to any one of claims 1 to 29, characterised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid n-butyl ester or a pharmaceutically acceptable salt thereof is manufactured. 54. A process according to any one of claims 1 to 29, characterised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid isobutyl ester or a pharmaceutically acceptable salt thereof is manufactured. 55. A process according to any one of claims 1 to 29, characterised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid n-pentyl ester or a pharmaceutically acceptable salt thereof is manufactured. 56. A process according to any one of claims 1 to 29, characterised in that E-2-amino-4-methyl-5-phosphono-3-pentenoic acid n-hexyl ester or a pharmaceutically acceptable salt thereof is manufactured. 87246/ 2 - 76 - 57. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid methyl ester or a pharmaceutically acceptable salt thereof is manufactured. 58. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid ethyl ester or a pharmaceutically acceptable salt thereof is manufactured. 59. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid n-propyl ester or a pharmaceutically acceptable salt thereof is manufactured. 60. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid n-butyl ester or a pharmaceutically acceptable salt thereof is manufactured. 61. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid isobutyl ester or a pharmaceutically acceptable salt thereof is manufactured. 62. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid n-pentyl ester or a pharmaceutically acceptable salt thereof is manufactured. 63. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, and 28, characterised in that E-2-amino-4-methyl-5-phos-phono-3-pentenoic acid n-hexyl ester or a pharmaceutically acceptable salt thereof is manufactured. 87246/3 - 77 - 64. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26, 28 and 31, characterised in that (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid or a pharmaceutically acceptable salt thereof is manufactured. 65. A process according to any one of claims 3, 5, 6, 8, 12, 15, 16, 18, 20, 23, 26 and 28, characterised in that (2R)-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester or a pharmaceutically acceptable salt thereof is manufactured. 66. (2R)-E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester or pharmaceutically acceptable salt thereof. 67. A pharmaceutical composition containing ( 2R)-E-2-amino-4-methyl-5-phosphono-3-pentenoic acid ethyl ester or a pharmaceutically acceptable salt thereof and customary pharmaceutical carriers. 68. A process according to anyone of claims 1 to 66, substantially as described and with particularly reference to the exam les. LUZZATTO & LUZZATTO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH298687 | 1987-08-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
IL87246A0 IL87246A0 (en) | 1989-03-31 |
IL87246A true IL87246A (en) | 1996-07-23 |
Family
ID=4246086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL8724688A IL87246A (en) | 1987-08-04 | 1988-07-28 | Process for the manufacture of phosphorus containing unsaturated 2-amino-alkanoic acid derivatives novel compounds and pharmaceutical compoistions containing them |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0302826A3 (en) |
JP (2) | JP2714018B2 (en) |
KR (1) | KR970011164B1 (en) |
AU (1) | AU605340B2 (en) |
CA (1) | CA1328113C (en) |
DD (1) | DD282016A5 (en) |
DK (1) | DK434788A (en) |
FI (1) | FI94415C (en) |
HU (1) | HU202242B (en) |
IL (1) | IL87246A (en) |
NO (1) | NO172495C (en) |
NZ (1) | NZ225649A (en) |
PH (1) | PH27591A (en) |
PT (1) | PT88170B (en) |
YU (1) | YU150188A (en) |
ZA (1) | ZA885653B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5175344A (en) * | 1986-02-13 | 1992-12-29 | Ciba-Geigy Corporation | Unsaturated amino acids |
ES2060122T3 (en) * | 1989-04-07 | 1994-11-16 | Ciba Geigy Ag | UNSATURATED DERIVATIVES OF AMINODICARBOXILIC ACIDS. |
US5488140A (en) * | 1989-09-26 | 1996-01-30 | Ciba-Geigy Corporation | 4-substituted 2-aminoalk-3-enoic |
US5294734A (en) * | 1989-09-26 | 1994-03-15 | Ciba-Geigy Corp. | 4-substituted 2-aminoalk-3-enoic acids |
DE59009368D1 (en) * | 1989-09-26 | 1995-08-10 | Ciba Geigy Ag | Phosphonic acid, process for its manufacture and use as an active pharmaceutical ingredient. |
US7414086B2 (en) | 2005-05-13 | 2008-08-19 | Shin-Etsu Chemical Co., Ltd. | Room temperature-curable organopolysiloxane compositions |
US20090170813A1 (en) * | 2005-10-18 | 2009-07-02 | Francine Acher | Hypophosphorous Acid Derivatives and their Therapeutical Applications |
JP4952952B2 (en) | 2008-09-12 | 2012-06-13 | 信越化学工業株式会社 | Method for producing room temperature curable organopolysiloxane composition |
EP3427729A1 (en) | 2017-07-13 | 2019-01-16 | Paris Sciences et Lettres - Quartier Latin | Probenecid for use in treating epileptic diseases, disorders or conditions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3775229D1 (en) * | 1986-02-13 | 1992-01-30 | Ciba Geigy Ag | UNSATURED AMINO ACIDS. |
-
1988
- 1988-07-27 EP EP19880810517 patent/EP0302826A3/en not_active Withdrawn
- 1988-07-27 PH PH37297A patent/PH27591A/en unknown
- 1988-07-28 IL IL8724688A patent/IL87246A/en not_active IP Right Cessation
- 1988-07-29 HU HU884036A patent/HU202242B/en not_active IP Right Cessation
- 1988-08-01 FI FI883589A patent/FI94415C/en not_active IP Right Cessation
- 1988-08-02 ZA ZA885653A patent/ZA885653B/en unknown
- 1988-08-02 PT PT88170A patent/PT88170B/en not_active IP Right Cessation
- 1988-08-02 CA CA000573557A patent/CA1328113C/en not_active Expired - Fee Related
- 1988-08-02 NZ NZ225649A patent/NZ225649A/en unknown
- 1988-08-02 DD DD88318584A patent/DD282016A5/en not_active IP Right Cessation
- 1988-08-03 YU YU01501/88A patent/YU150188A/en unknown
- 1988-08-03 AU AU20389/88A patent/AU605340B2/en not_active Ceased
- 1988-08-03 NO NO88883444A patent/NO172495C/en unknown
- 1988-08-03 KR KR1019880009879A patent/KR970011164B1/en not_active IP Right Cessation
- 1988-08-03 DK DK434788A patent/DK434788A/en not_active Application Discontinuation
- 1988-08-04 JP JP63195303A patent/JP2714018B2/en not_active Expired - Lifetime
-
1997
- 1997-06-25 JP JP9169028A patent/JPH1053597A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0302826A2 (en) | 1989-02-08 |
DD282016A5 (en) | 1990-08-29 |
PT88170A (en) | 1989-06-30 |
NO172495B (en) | 1993-04-19 |
ZA885653B (en) | 1989-04-26 |
JP2714018B2 (en) | 1998-02-16 |
KR890003786A (en) | 1989-04-18 |
FI883589A0 (en) | 1988-08-01 |
DK434788D0 (en) | 1988-08-03 |
EP0302826A3 (en) | 1991-04-03 |
DK434788A (en) | 1989-02-05 |
NZ225649A (en) | 1991-05-28 |
YU150188A (en) | 1990-04-30 |
NO883444D0 (en) | 1988-08-03 |
JPH0248586A (en) | 1990-02-19 |
AU605340B2 (en) | 1991-01-10 |
NO883444L (en) | 1989-02-06 |
FI94415C (en) | 1995-09-11 |
PT88170B (en) | 1995-03-01 |
CA1328113C (en) | 1994-03-29 |
JPH1053597A (en) | 1998-02-24 |
KR970011164B1 (en) | 1997-07-08 |
IL87246A0 (en) | 1989-03-31 |
HUT47947A (en) | 1989-04-28 |
FI94415B (en) | 1995-05-31 |
HU202242B (en) | 1991-02-28 |
FI883589A (en) | 1989-02-05 |
PH27591A (en) | 1993-08-31 |
NO172495C (en) | 1993-07-28 |
AU2038988A (en) | 1989-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2705979B2 (en) | Method for producing phosphorus-containing L-amino acids, esters of the amino acids and N-derivatives | |
US5202327A (en) | Phosphorus-containing hmg-coa reductase inhibitors | |
AU610493B2 (en) | Unsaturated amino acids | |
WO1994009016A1 (en) | 2-piperidinecarboxylic acid derivatives useful as nmda receptor antagonists | |
US5051413A (en) | Unsaturated amino acids | |
IL87246A (en) | Process for the manufacture of phosphorus containing unsaturated 2-amino-alkanoic acid derivatives novel compounds and pharmaceutical compoistions containing them | |
IL95936A (en) | (r)-(-)-4-hydroxy-alpha' [[[6-(4-phenylbutoxy) hexyl]-1,3-benzenedimethanol its preparation and pharmaceutical compositions containing it | |
US5461040A (en) | Substituted aminoalkylphosphinic acids | |
US5567840A (en) | Substituted aminoalkylphosphinic acids | |
US5175344A (en) | Unsaturated amino acids | |
US5134134A (en) | Unsaturated aminodicarboxylic acid derivatives | |
FI97231B (en) | Process for the preparation of 4-substituted 2-aminoalk-3-enoic acids | |
FI86849B (en) | FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA AZEPINONDERIVAT OCH VID FOERFARANDET ANVAENDBARA MELLANPRODUKTER. | |
US5583123A (en) | Certain tetrazole derivatives | |
SI8811501A (en) | Process for the preparation of new unsaturated amino acide compounds | |
US5488140A (en) | 4-substituted 2-aminoalk-3-enoic | |
GB2247236A (en) | 4,7-Dihydro-furo[3,4-d]pyrimidin-5(1H)-one derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
RH | Patent void |